Quiver News

The Safari Collection is a world-renowned luxury safari company and owner of the Giraffe Manor

This is another leading safari company in Africa that has placed an order with Tembo

The first order was from Asilia Africa announced in February 2025

Tembo's solutions selected to drive sustainable safari experiences across Kenya

LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ: VVPR, the “Company”) is pleased to announce that its wholly-owned subsidiary, Tembo e-LV, has secured an inaugural order for its EV conversion kits from The Safari Collection, owner of luxury properties in Kenya, including the Giraffe Manor, Sasaab, Sala's Camp and Solio Lodge.

Established in 2009 by conservationists and safari entrepreneurs, Tanya and Mikey Carr-Hartley, The Safari Collection is a privately owned portfolio of distinctive luxury camps and lodges set in some of the most breathtaking locations across Kenya. Born from a deep passion for sharing the magic of Africa with the world, the company has grown into a leading name in bespoke safari experiences. With a strong focus on sustainable environmental practices and community empowerment, The Safari Collection plays a vital role in creating meaningful economic opportunities for the people of Kenya, all while preserving the extraordinary natural heritage of the region.

Tanya Carr-Hartley, Co-Founder of The Safari Collection, said: “At the Safari Collection, our commitment to preserving Kenya’s wild beauty goes hand in hand with innovation. Partnering with Tembo to electrify our vehicle fleet is a natural extension of our mission – to offer world-class safari experiences while treading lightly on the land we so deeply cherish. This is not just about mobility; it’s about sustainability, legacy, and protecting the places we love for future generations.”

Mikey Carr-Hartley, Co-Founder of The Safari Collection, said: “Our lodges are located in some of the most pristine, remote landscapes in Africa. Switching to electric safari vehicles helps ensure these extraordinary ecosystems remain intact – not only for our guests today, but for our children tomorrow. After having evaluated a number of alternative options, we decided to proceed with Tembo as their solutions were superior and more cost effective than other offerings in the market.”

Matthew Nestor, VivoPower’s Global Head of Partnerships and Sales, said: “We’re thrilled to partner with The Safari Collection, an organisation whose values of conservation, innovation, and local stewardship closely mirror our own. By electrifying their safari fleet, they’re not just leading by example in eco-tourism, but also proving that luxury and sustainability can go hand in hand, even in the most rugged environments.”

About VivoPower

Established in 2014 and listed on Nasdaq since 2016, VivoPower is an award-winning global sustainable energy solutions B Corporation company focussed on electric solutions for off-road and on-road customised and ruggedised fleet applications as well as ancillary financing, charging, battery and microgrids solutions. VivoPower’s core purpose is to provide its customers with turnkey decarbonisation solutions that enable them to move toward net-zero carbon status. VivoPower has operations and personnel covering Australia, Canada, the Netherlands, the United Kingdom, the United States, the Philippines, and the United Arab Emirates.

About Tembo

Tembo electric utility vehicles (EUVs) are a 100% electric solution for ruggedised and/or customised applications for fleet owners in the mining, agriculture, energy utilities, defence, police, construction, infrastructure, government, humanitarian, and game safari industries. Tembo provides safe, high-performance off-road and on-road electric utility vehicles. Its core purpose is to provide safe and reliable electrification solutions for utility vehicle fleet owners, helping to perpetuate useful life, reduce costs, maximise return on assets, meet ESG goals and seeks to further the circular economy. Tembo is a subsidiary of VivoPower, a Nasdaq-listed B Corporation.

About The Safari Collection

Founded by Tanya and Mikey Carr-Hartley in 2009, The Safari Collection is a family-run portfolio offering immersive experiences at six unique properties in the finest locations in Kenya. The Carr-Hartleys are a family passionate about adventure, the spectacular un-spoilt wilderness areas of their home country and protecting it for future generations. It is from this pioneering spirit and love for Kenya’s wildest corners that The Safari Collection was born. The energy and passion of their dynamic team flows through everything that they do. The Safari Collection's authentic, first-hand knowledge spans the entire region to create unique, cutting-edge experiences.

Forward-Looking Statements

This communication includes certain statements that may constitute “forward-looking statements” for purposes of the U.S. federal securities laws. Forward-looking statements include, but are not limited to, statements that refer to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about the achievement of performance hurdles, or the benefits of the events or transactions described in this communication and the expected returns therefrom. These statements are based on VivoPower’s management’s current expectations or beliefs and are subject to risk, uncertainty, and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive and/or regulatory factors, and other risks and uncertainties affecting the operation of VivoPower’s business. These risks, uncertainties and contingencies include changes in business conditions, fluctuations in customer demand, changes in accounting interpretations, management of rapid growth, intensity of competition from other providers of products and services, changes in general economic conditions, geopolitical events and regulatory changes, and other factors set forth in VivoPower’s filings with the United States Securities and Exchange Commission. The information set forth herein should be read in light of such risks. VivoPower is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements whether as a result of new information, future events, changes in assumptions or otherwise.

Contact

Shareholder Enquiries

shareholders@vivopower.com

PROVO, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Champion Safe Company, a leading manufacturer of premium safes and wholly-owned subsidiary of American Rebel Holdings, Inc. (NASDAQ: AREB), America’s Patriotic Brand ( americanrebel.com ), is proud to announce a strong and successful presence at the 154th NRA Annual Meetings & Exhibits held this past weekend in Atlanta, Georgia. Champion’s booth saw steady traffic and enthusiastic interest from NRA members passionate about protecting their firearms, their families, and their Second Amendment rights.

“Our team was energized by the incredible passion and patriotism of the NRA members we met in Atlanta,” said Tom Mihalek, CEO of Champion Safe Company. “It’s clear that Champion’s commitment to building safes with American-made steel and uncompromising strength really resonates with people who care deeply about freedom and security.”

Throughout the event, attendees explored Champion’s full lineup of gun safes and vault doors, drawn to the company’s reputation for superior strength, fire protection, and craftsmanship. Many took advantage of show specials, and the strong interest in Champion products led to a significant boost to the brand during the weekend.

“The NRA Annual Meeting is a reminder of why we do what we do,” Mihalek added. “Champion safes are built to protect the rights, values, and possessions that matter most to Americans.”

Champion Safe Company extends its thanks to the NRA, the City of Atlanta, The Atlanta Safe House and the thousands of attendees who made the 154th Annual Meeting a tremendous success.

For more information about Champion Safe, visit championsafe.com .

About Champion Safe Company

Champion Safe Company has been at the forefront of safe manufacturing for over 25 years, offering a range of high-quality safes designed for ultimate security and fire protection. With a commitment to craftsmanship and innovation, Champion Safes are trusted by homeowners, gun owners, and businesses across the nation.

About American Rebel Holdings, Inc.

American Rebel Holdings, Inc. (NASDAQ: AREB) has operated primarily as a designer, manufacturer and marketer of branded safes and personal security and self-defense products and has recently transitioned into the beverage industry through the introduction of American Rebel Beer. The Company also designs and produces branded apparel and accessories. To learn more, visit americanrebel.com and americanrebelbeer.com . For investor information, visit americanrebel.com/investor-relations .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. American Rebel Holdings, Inc., (NASDAQ: AREB; AREBW) (the “Company,” "American Rebel,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words "forecasts" "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements primarily on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include benefits of the meeting, actual effect of the meeting on sales, margin and profit growth, our ability to effectively execute our business plan, and the Risk Factors contained within AREB’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and Form 10-Q for the nine months ended September 30, 2024. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

Contact:
ir@americanrebel.com

App Now Available for Download, Expanding Fort’s Direct-to-Consumer Digital Offering

Tel Aviv, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, announced today that its wholly-owned subsidiary, Fort Products Limited (“Fort”), has officially launched its innovative AI-powered pest control mobile app on the Apple App Store.

The successful approval and launch mark a major milestone in Jeffs’ Brands’ strategy to expand its direct-to-consumer digital presence. Fort’s app empowers users to easily identify household pests using artificial intelligence (“AI”) and offers customized treatment recommendations based on the type of pest, infestation severity, and user preferences. Additionally, the app provides curated product suggestions, featuring Fort’s proprietary pest control solutions.

“We are proud to officially bring our AI-powered pest control solution to users worldwide,” said Victor Hakmon, CEO of Jeffs’ Brands. “We believe that the launch of Fort’s app on the Apple App Store represents a significant step forward in our mission to deliver smart, accessible, and effective pest control tools directly to consumers.”

The app underwent extensive internal testing to ensure a seamless, intuitive user experience across a wide range of devices. With its real-time pest identification and treatment recommendations, we believe that Fort’s app positions the Company at the forefront of digital transformation in the pest control market.

Fort is also progressing with the its Android version of the app, which was already submitted and expected to be available on Google Play in the near future.

This milestone follows Jeffs’ Brands’ previously announced efforts to expand its digital footprint, combining innovative technology with its growing portfolio of consumer brands.

About Jeffs’ Brands Ltd

Jeffs' Brands aims to transform the world of e-commerce by creating and acquiring products and turning them into market leaders, tapping into vast, unrealized growth potential. Through the Company’s management team’s insight into the FBA Amazon business model, it aims to use both human capability and advanced technology to take products to the next level. For more information on Jeffs’ Brands Ltd visit https://jeffsbrands.com .

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, we are using forward-looking statements when discussing the belief that the approval and launch of the pest control app marks a major milestone in Jeffs’ Brands’s strategy to expand its direct-to-consumer digital presence, the belief that the launch of Fort’s app on the Apple App Store represents a significant step forward in the Company’s mission to deliver smart, accessible, and effective pest control tools directly to consumers, the belief that Fort’s app positions the Company at the forefront of digital transformation in the pest control market, and the expectation that the app will become available on Google Play in the near future. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to adapt to significant future alterations in Amazon’s policies; our ability to sell our existing products and grow our brands and product offerings, including by acquiring new brands; our ability to meet our expectations regarding the revenue growth and the demand for e-commerce; the overall global economic environment; the impact of competition and new e-commerce technologies; general market, political and economic conditions in the countries in which we operate; projected capital expenditures and liquidity; the impact of possible changes in Amazon’s policies and terms of use; the impact of the conditions in Israel, including the recent attacks by Hamas, Iran, and other terrorist organizations; and the other risks and uncertainties described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (“SEC”), on March 31, 2025 and our other filings with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact:

Michal Efraty
Adi and Michal PR- IR
Investor Relations, Israel
michal@efraty.com

LAS VEGAS, April 28, 2025 (GLOBE NEWSWIRE) -- AGS (NYSE: AGS), a leading supplier of high-performing slot, table, and interactive products and services to the global gaming industry, today announced the appointment of Daniel “Dan” Marcus as Vice President of Product Management. Marcus will report to Mark DeDeaux, Senior Vice President and General Manager of Slots, and work together with Jackson Floyd, Vice President of Slots, to tackle strategic objectives across the slot products business.

In this role, Marcus will serve as a critical bridge between AGS’ R&D and Sales teams, aligning product strategy and execution across departments. He will lead the full lifecycle of AGS’ slot portfolio—from roadmap development and market release planning to product catalog management and sales enablement. He will also oversee cross-functional alignment across engineering, business development, and marketing to support go-to-market readiness. His responsibilities include managing AGS’ slot footprint throughout North America.

“Dan is a strategic product leader with a deep understanding of both the operational and analytical sides of the gaming business,” said DeDeaux. “His ability to connect product vision with market needs makes him the right person to help accelerate our momentum. As we scale our portfolio and expand into new markets, Dan’s leadership will be critical to driving the next phase of AGS’ growth.”

With over 20 years of experience in the gaming industry, Marcus has held leadership roles at IGT, Bally Technologies, DraftKings, Hard Rock Digital, Hard Rock Hotel & Casino and Harrah’s Entertainment. He has consistently led high-impact initiatives across product development, performance analytics, and go-to-market strategy. His past work includes overseeing commercial strategy for IGT’s premium segment and founding Bally’s performance consulting group.

About AGS

AGS is a global company focused on creating a diverse mix of entertaining gaming experiences for every kind of player. Our roots are firmly planted in the Class II Native American gaming market, and our customer-centric culture and growth have helped us branch out to become a leading all-inclusive commercial gaming supplier. Powered by high-performing Class II and Class III slot products, an expansive table products portfolio, real-money gaming platforms and content, highly rated social casino solutions for operators and players, and best-in-class service, we offer an unmatched value proposition for our casino partners. Learn more at www.playags.com .

AGS Media Contact:
Julia Boguslawski, Chief Marketing Officer
Nikki Davis, Director, Marketing & Communications
PR@PlayAGS.com

AGS Investor Contact:
Brad Boyer, Senior Vice President of Corporate Development & Capital Markets
Investors@PlayAGS.com

©2025 AGS LLC. All® notices signify marks registered in the United States. All ™ and ℠ notices signify trademarks, which are not registered on any country-wide basis. Products referenced herein are sold by AGS LLC or other subsidiaries of PlayAGS, Inc.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/01a9eb19-ef48-4a43-bc4d-67c5af424c41

TEL AVIV, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE) (“REE” or the “Company”), an automotive technology company that develops and builds software-defined vehicle technology and provider of full by-wire electric trucks and platforms, today announced a 2024 business update and that it reschedules the release date of its fourth-quarter and fiscal year 2024 financial results to before the market opens on Thursday, May 15, 2025, as it requires additional time to complete the Annual Report. The Company does not anticipate any material changes to the financial results included in today’s announcement.

2024 Business Highlights

1. Increased reservations ¹ to nearly $1 billion as demand for REE’s software defined vehicles (SDV) technology and powered by REE vehicles remains strong and continues to grow.
2. First U.S. Deliveries Expected in the First Half of 2025 . Collaboration with Motherson Group aims to solidify REE’s supply chain and collaboration with Roush Industries provides capabilities to deliver SDVs.
3. Signed MOU with one of the leading technology companies for REE’s SDV technology , aiming to expand REE’s access into the global, public autonomous transportation vehicle market, having already received certain up-front fees related to the project.
4. Achieved Important Technology Milestones including first Federal Motor Vehicle Safety Standards (FMVSS) certification of a full by-wire vehicle, completion of first autonomous drive on an active runway with Airbus UpNext, introduction of REEai Cloud and collaboration with Geotab. Milestones demonstrate the growth opportunity for REE as key enabler of next generation electric, autonomous, and connected commercial vehicles.

“2024 was a defining year for REE. After more than a decade of innovation and execution, we are expecting the deliveries of commenced production of our SDV, the P7-C, the world’s first FMVSS-certified, full by-wire commercial vehicle certified for public roads in the United States, and we expect deliveries in the first half of 2025. We are seeing strong market validation with reservations reaching nearly $1 billion,” said Daniel Barel, Co-Founder and Chief Executive Officer of REE.

“We started this journey over a decade ago and, in 2024, we witnessed our vision come to life. With expected deliveries of our first vehicles beginning in the coming months, strategic partners in place, a large service network and growing demand from tech companies, fleet managers and OEMs alike, 2025 is expected to continue REE on this trajectory. We look forward to discussing in more detail as well as provide an update our current outlook for 2025 during our call on May 15, 2025.”

1) Reservations include both binding sales orders and non-binding capacity reservations, including those from our MOU. Reservations are intended to include deliveries over the next few years. There is no guarantee that these reservations will materialize.

Q4 and 2024 Year-End Preliminary Unaudited Select Financial Results

• Expected $72.3 million in cash & cash equivalents and short-term investments as of December 31, 2024 (inclusive of a $18 million credit facility) compared to $85.6 million in cash & cash equivalents and short-term investments as of December 31, 2023 (inclusive of a $15 million credit facility).
• Expected U.S. Generally Accepted Accounting Principles (GAAP) net loss in 2024 of $111.8 million, or $7.01 loss per share, compared to $114.2 million, $11.32 loss per share, in 2023.
• Expected fourth quarter 2024 GAAP net loss of $37.3 million, or $1.51 loss per share, compared to $38.5 million, or $2.56 loss per share, in Q3 2024 and $35.2 million, or $3.44 loss per share, in Q4 2023.
  

The preliminary results presented reflect the Company’s estimates based solely upon information available, and the Company’s final results could differ from these estimates due to the completion of the Company’s financial closing procedures, final adjustments and other developments that may arise between now and the time such audited consolidated financial statements for the year ended December 31, 2024 are issued. The Company expects to release the fully audited 2024 financial statements on or before May 15, 2025.

Earnings Release and Call Information

In accordance with today's announcement, the Company will file a Notification of Late Filing on Form 12b-25 with the U.S. Securities and Exchange Commission with respect to its Annual Report on Form 20-F (the “Annual Report”) for the fiscal year ended December 31, 2024. In accordance with Form 12b-25, the Company is rescheduling the release date of its fourth-quarter and fiscal year 2024 financial results to before the market opens on Thursday, May 15, 2025. The Company does not anticipate any material changes to the financial results included in today’s announcement. A webcast and conference call will be held on the same day at 8:30 a.m. ET to review the Company’s financial results and discuss recent events and conduct a question-and-answer session.

Investors may submit questions for consideration by emailing investors@ree.auto .

Event: REE’s Fourth-Quarter and Fiscal Year 2024 Financial Results Conference Call
Date: Thursday, May 15, 2025
Time: 8:30 a.m. ET
Conference Call Dial-In: LINK

Webcast Registration: LINK
Add to calendar: LINK

To learn more about REE Automotive’s patented technology and unique value proposition that position the company to break new ground in e-mobility, visit www.ree.auto .

About REE Automotive
REE Automotive Ltd. (Nasdaq: REE) is a technology company enabling the next generation of software-defined vehicles (SDVs). Powered by REE ^® vehicles manage operations and features through proprietary software, enhancing safety, modularity and performance in passenger and commercial vehicles. At the core of REE’s SDV technology is a single unified layer powered by the company’s system-on-chip, redundant architecture capable of real-time, complex decision making on vehicle dynamics, energy management and autonomy. REE has a global supply chain managed by multibillion dollar international supplier, Motherson Group, REE’s second largest investor. Together with a leading automotive manufacturer in Detroit, REE can produce Powered by REE vehicles at scale without the need for capital-intensive investment. REE’s SDV technology licensing is a solution for OEMs seeking to improve their cost structure, reduce time to market and enhance their product offering. The company is targeting the first deliveries of its flagship P7-C electric truck in the first half of 2025, and plans for continued growth by completing, not competing with global OEMs' future vehicle lineups. With a validated and certified SDV architecture, REE helps automakers and fleet operators unlock new mobility possibilities. Learn more at www.ree.auto .

Media Contact
Malory Van Guilder
Skyya PR for REE Automotive
+1 651-335-0585
ree@skyya.com

Investor Contact
Dana Rubinstein
Chief Strategy Officer for REE Automotive
investors@ree.auto

Caution About Forward-Looking Statements

This communication includes certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding REE or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. For example, REE is using forward-looking statements when it discusses the date of the expected filing of its Annual Report, the benefits of its collaborations with Motherson Group and Roush Industries, the expected timing of the delivery of the P7-Cs, and its preliminary unaudited estimates of its cash & cash equivalents and short-term investments and GAAP net loss for the quarter and fiscal year ended December 31, 2024. In addition, any statements that refer to plans, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “aim” “anticipate,” “appear,” “approximate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “would”, “designed,” “target” and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All statements, other than statements of historical facts, may be forward-looking statements.

These forward-looking statements are based on REE’s current expectations and assumptions about future events and are based on currently available information as of the date of this communication and current expectations, forecasts, and assumptions. Although REE believes that the expectations reflected in forward-looking statements are reasonable, such statements involve an unknown number of risks, uncertainties, judgments, and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These factors are difficult to predict accurately and may be beyond REE’s control. Forward-looking statements in this communication speak only as of the date made and REE undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. In light of these risks and uncertainties, investors should keep in mind that results, events or developments discussed in any forward-looking statement made in this communication may not occur.

Uncertainties and risk factors that could affect REE’s future performance and could cause actual results to differ include, but are not limited to: REE’s ability to commercialize its strategic plan, including its plan to successfully evaluate, obtain regulatory approval, produce and market its P7 lineup; REE’s ability to maintain and advance relationships with current Tier 1 suppliers and strategic partners; development of REE’s advanced prototypes into marketable products; REE’s ability to grow and scale manufacturing capacity through relationships with Tier 1 suppliers; REE’s estimates of unit sales, expenses and profitability and underlying assumptions; REE’s reliance on its UK Engineering Center of Excellence for the design, validation, verification, testing and homologation of its products; REE’s limited operating history; risks associated with building out of REE’s supply chain; risks associated with plans for REE’s initial commercial production; REE’s dependence on suppliers and potential suppliers, which include single or limited source suppliers; development of the market for commercial EVs; risks associated with data security breach, failure of information security systems and privacy concerns; risks related to a lack of compliance with Nasdaq’s minimum bid price requirement or other Nasdaq listing rules; future sales of our securities by existing material shareholders or by us that could cause the market price for the Class A Ordinary Shares to decline; potential disruption of shipping routes due to accidents, political events, international hostilities and instability, piracy or acts by terrorists; intense competition in the e-mobility space, including with competitors who have significantly more resources; risks related to the fact that REE is incorporated in Israel and governed by Israeli law; REE’s ability to make continued investments in its platform; the impact of fluctuations in interest rates, inflation, and foreign exchange rates; the ongoing conflict between Ukraine and Russia and any other worldwide health epidemics or outbreaks that may arise and adverse global conditions, including macroeconomic and geopolitical uncertainty; the global economic environment, the general market, political and economic conditions in the countries in which we operate (including the recent policy changes by the Trump Administration); the ongoing Gaza war and other military conflict in Israel; the need to attract, train and retain highly-skilled technical workforce; changes in laws and regulations that impact REE; REE’s ability to enforce, protect and maintain intellectual property rights; REE’s ability to retain engineers and other highly qualified employees to further its goals; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in REE’s annual report filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 27, 2024 and in subsequent filings with the SEC.

FortiGuard Labs 2025 Global Threat Landscape Report highlights a boom in Cybercrime-as-a-Service on the darknet, fueling a lucrative market for credentials, exploits, and access

SUNNYVALE, Calif., April 28, 2025 (GLOBE NEWSWIRE) --

News Summary

Fortinet ^® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, today announced the release of the 2025 Global Threat Landscape Report from FortiGuard Labs . The latest annual report is a snapshot of the active threat landscape and trends from 2024, including a comprehensive analysis across all tactics used in cyberattacks, as outlined in the MITRE ATT&CK framework. The data reveals that threat actors are increasingly harnessing automation, commoditized tools, and AI to systematically erode the traditional advantages held by defenders.

“Our latest Global Threat Landscape Report makes one thing clear: Cybercriminals are accelerating their efforts, using AI and automation to operate at unprecedented speed and scale,” said Derek Manky, Chief Security Strategist and Global VP Threat Intelligence, Fortinet FortiGuard Labs. “The traditional security playbook is no longer enough. Organizations must shift to a proactive, intelligence-led defense strategy powered by AI, zero trust, and continuous threat exposure management to stay ahead of today’s rapidly evolving threat landscape.”

Key findings from the latest FortiGuard Labs Global Threat Landscape Report include:

• Automated scanning hits record highs as attackers shift left to identify exposed targets early . To capitalize on newfound vulnerabilities, cybercriminals are deploying automated scanning at a global scale. Active scanning in cyberspace reached unprecedented levels in 2024, rising by 16.7% worldwide year-over-year, highlighting a sophisticated and massive collection of information on exposed digital infrastructure. FortiGuard Labs observed billions of scans each month, equating to 36,000 scans per second, revealing an intensified focus on mapping exposed services such as SIP and RDP and OT/IoT protocols like Modbus TCP.
• Darknet marketplaces fuel easy access to neatly packaged exploit kits . In 2024, cybercriminal forums increasingly operated as sophisticated marketplaces for exploit kits, with over 40,000 new vulnerabilities added to the National Vulnerability Database, a 39% rise from 2023. In addition to zero-day vulnerabilities circulating on the darknet, initial access brokers are increasingly offering corporate credentials (20%), RDP access (19%), admin panels (13%), and web shells (12%). Additionally, FortiGuard Labs observed a 500% increase in the past year in logs available from systems compromised by infostealer malware, with 1.7 billion stolen credential records shared in these underground forums.
• AI-powered cybercrime is scaling rapidly . Threat actors are harnessing AI to enhance phishing realism and evading traditional security controls, making cyberattacks more effective and difficult to detect. Tools like FraudGPT, BlackmailerV3, and ElevenLabs are fueling more scalable, believable, and effective campaigns, without the ethical restrictions of publicly available AI tools.
• Targeted attacks on critical sectors intensify . Industries such as manufacturing, healthcare, and financial services continue to experience a surge in tailored cyberattacks, with adversaries deploying sector-specific exploitations. In 2024, the most targeted sectors were manufacturing (17%), business services (11%), construction (9%), and retail (9%). Both nation-state actors and Ransomware-as-a-Service (RaaS) operators concentrated their efforts on these verticals, with the United States bearing the brunt of attacks (61%), followed by the United Kingdom (6%) and Canada (5%).
• Cloud and IoT security risks escalate . Cloud environments continue to be a top target, with adversaries exploiting persistent weaknesses such as open storage buckets, over-permissioned identities, and misconfigured services. In 70% of observed incidents, attackers gained access through logins from unfamiliar geographies, highlighting the critical role of identity monitoring in cloud defense.
• Credentials are the currency of cybercrime . In 2024, cybercriminals shared over 100 billion compromised records on underground forums, a 42% year-over-year spike, driven largely by the rise of “combo lists” containing stolen usernames, passwords, and email addresses. More than half of darknet posts involved leaked databases, enabling attackers to automate credential-stuffing attacks at scale. Well-known groups like BestCombo, BloddyMery, and ValidMail were the most active cybercriminal groups during this time and continue to lower the barrier to entry by packaging and validating these credentials, fueling a surge in account takeovers, financial fraud, and corporate espionage.

CISO Takeaway: Strengthening Cyber Defenses Against Emerging Threats
Fortinet’s Global Threat Landscape Report provides rich details on the latest attacker tactics and techniques while also delivering prescriptive recommendations and actionable insights. Designed to empower CISOs and security teams, the report offers strategies to counter threat actors before they strike, helping organizations stay ahead of emerging cyberthreats.

This year’s report includes a “CISO Playbook for Adversary Defense” that highlights a few strategic areas to focus on:

• S hifting from traditional threat detection to continuous threat exposure management : This proactive approach emphasizes continuous attack surface management, real-world emulation of adversary behavior, risk-based remediation prioritization, and automation of detection and defense responses. Utilizing breach and attack simulation (BAS) tools to regularly assess endpoint, network, and cloud defenses against real-world attack scenarios ensures resilience against lateral movement and exploitation.
• Simulating real-world attacks : Conduct adversary emulation exercises, red and purple teaming, and leverage MITRE ATT&CK to test defenses against threats like ransomware and espionage campaigns.
• Reducing attack surface exposure : Deploy attack surface management (ASM) tools to detect exposed assets, leaked credentials, and exploitable vulnerabilities while continuously monitoring darknet forums for emerging threats.
• Prioritizing high-risk vulnerabilities : Focus remediation efforts on vulnerabilities actively discussed by cybercrime groups, leveraging risk-based prioritization frameworks such as EPSS and CVSS for effective patch management.
• Leveraging dark web intelligence : Monitor darknet marketplaces for emerging ransomware services and track hacktivist coordination efforts to preemptively mitigate threats like DDoS and web defacement attacks.
  

Discover how FortiGuard Labs Advisory Services combine cutting-edge technology and expert services to help organizations strengthen their security posture before threats emerge. In the event of an incident, FortiGuard Labs offers swift, effective response and in-depth forensic analysis to minimize impact and prevent future intrusions, delivering comprehensive protection in today’s increasingly volatile digital landscape.

Additional Resources

• Download a copy of the 2025 Global Threat Landscape Report from FortiGuard Labs.
• Read the blog for valuable takeaways from this research.
• Learn more about FortiGuard Labs threat intelligence and research and outbreak alerts, which provide timely steps to mitigate breaking cybersecurity attacks.
• Learn about FortiAI and Fortinet’s AI-driven innovations.
• Read more about the Fortinet Security Fabric, which brings end-to-end security to organizations of all sizes to prevent ransomware across all points of entry.
• Visit fortinet.com/trust to learn about Fortinet innovation, collaboration partners, product security processes, and enterprise-grade products.
• Read about how Fortinet customers are securing their organizations.
• Learn about Fortinet's commitment to product security and integrity , including its responsible product development and vulnerability disclosure approach and policies.
• Follow Fortinet on X , LinkedIn , Facebook , and Instagram . Subscribe to Fortinet on our blog or YouTube .

About Fortinet
Fortinet (Nasdaq: FTNT) is a driving force in the evolution of cybersecurity and the convergence of networking and security. Our mission is to secure people, devices, and data everywhere, and today we deliver cybersecurity everywhere our customers need it with the largest integrated portfolio of over 50 enterprise-grade products. Well over half a million customers trust Fortinet's solutions, which are among the most deployed, most patented, and most validated in the industry. The Fortinet Training Institute , one of the largest and broadest training programs in the industry, is dedicated to making cybersecurity training and new career opportunities available to everyone. Collaboration with esteemed organizations from both the public and private sectors, including Computer Emergency Response Teams (“CERTS”), government entities, and academia, is a fundamental aspect of Fortinet’s commitment to enhance cyber resilience globally. FortiGuard Labs , Fortinet’s elite threat intelligence and research organization, develops and utilizes leading-edge machine learning and AI technologies to provide customers with timely and consistently top-rated protection and actionable threat intelligence. Learn more at https://www.fortinet.com , the Fortinet Blog , and FortiGuard Labs .

Copyright © 2025 Fortinet, Inc. All rights reserved. The symbols ® and ™ denote respectively federally registered trademarks and common law trademarks of Fortinet, Inc., its subsidiaries and affiliates. Fortinet’s trademarks include, but are not limited to, the following: Fortinet, the Fortinet logo, FortiGate, FortiOS, FortiGuard, FortiCare, FortiAnalyzer, FortiManager, FortiASIC, FortiClient, FortiCloud, FortiMail, FortiSandbox, FortiADC, FortiAI, FortiAIOps, FortiAgent, FortiAntenna, FortiAP, FortiAPCam, FortiAuthenticator, FortiCache, FortiCall, FortiCam, FortiCamera, FortiCarrier, FortiCASB, FortiCentral, FortiCNP, FortiConnect, FortiController, FortiConverter, FortiCSPM, FortiCWP, FortiDAST, FortiDB, FortiDDoS, FortiDeceptor, FortiDeploy, FortiDevSec, FortiDLP, FortiEdge, FortiEDR, FortiExplorer, FortiExtender, FortiFirewall, FortiFlex FortiFone, FortiGSLB, FortiGuest, FortiHypervisor, FortiInsight, FortiIsolator, FortiLAN, FortiLink, FortiMonitor, FortiNAC, FortiNDR, FortiPAM, FortiPenTest, FortiPhish, FortiPoint, FortiPolicy, FortiPortal, FortiPresence, FortiProxy, FortiRecon, FortiRecorder, FortiSASE, FortiScanner, FortiSDNConnector, FortiSIEM, FortiSMS, FortiSOAR, FortiSRA, FortiStack, FortiSwitch, FortiTester, FortiToken, FortiTrust, FortiVoice, FortiWAN, FortiWeb, FortiWiFi, FortiWLC, FortiWLM, FortiXDR and Lacework FortiCNAPP. Other trademarks belong to their respective owners. Fortinet has not independently verified statements or certifications herein attributed to third parties and Fortinet does not independently endorse such statements. Notwithstanding anything to the contrary herein, nothing herein constitutes a warranty, guarantee, contract, binding specification or other binding commitment by Fortinet or any indication of intent related to a binding commitment, and performance and other specification information herein may be unique to certain environments.

SHANGHAI, China, April 28, 2025 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission (the “SEC”) on April 28, 2025 U.S. Eastern Time.

The annual report can be accessed on the Company’s investor relations website at investors.gds-services.com and on the SEC’s website at www.sec.gov. The Company will provide hardcopies of the annual report, free of charge, to its shareholders and ADS holders upon request. Requests should be submitted to ir@gds-services.com .

About GDS Holdings Limited

GDS Holdings Limited (NASDAQ: GDS; HKEX: 9698) is a leading developer and operator of high-performance data centers in China. The Company’s facilities are strategically located in and around primary economic hubs where demand for high-performance data center services is concentrated. The Company’s data centers have large net floor area, high power capacity, density and efficiency, and multiple redundancies across all critical systems. GDS is carrier and cloud-neutral, which enables its customers to access the major telecommunications networks, as well as the largest PRC and global public clouds, which are hosted in many of its facilities. The Company offers co-location and a suite of value-added services, including managed hybrid cloud services through direct private connection to leading public clouds, managed network services, and, where required, the resale of public cloud services. The Company has a 24-year track record of service delivery, successfully fulfilling the requirements of some of the largest and most demanding customers for outsourced data center services in China. The Company’s customer base consists predominantly of hyperscale cloud service providers, large internet companies, financial institutions, telecommunications carriers, IT service providers, and large domestic private sector and multinational corporations. The Company also holds a non-controlling 35.6% equity interest in DayOne Data Centers Limited which develops and operates data centers in International markets.

For investor and media inquiries, please contact:

GDS Holdings Limited
Laura Chen
Phone: +86 (21) 2029-2203
Email: ir@gds-services.com

Piacente Financial Communications
Ross Warner
Phone: +86 (10) 6508-0677
Email: GDS@tpg-ir.com

Brandi Piacente
Phone: +1 (212) 481-2050
Email: GDS@tpg-ir.com

GDS Holdings Limited

MIAMI and SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- RSA Conference Booth N-5658 – Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, announced the industry’s first always-on AI risk defense that continuously identifies data exposure in real time, flags violations, and automatically fixes issues before they can become data breaches.

In organizations with poor data security posture, employees and AI agents are only one action away from accessing troves of data they should never have had access to in the first place.

Varonis AI Shield continuously analyzes your AI security posture, monitors how AI interacts with data, and dynamically right-sizes permissions so that sensitive information isn’t exposed due to poor data security hygiene.

AI Shield makes intelligent decisions about which data to restrict from AI using Varonis’ patented permissions analysis algorithms that factor in data sensitivity, staleness, user profile, and more. Even if you haven’t right-sized access, AI Shield has you covered.

“AI makes the data security challenge much more urgent and complex,” said Varonis EVP of Engineering and Chief Technology Officer David Bass. “AI Shield gives our customers the confidence to deploy AI with both preventative and detective controls that require zero setup and maintenance. It’s always on, always learning, and always working for you behind the scenes to prevent breaches and compliance violations.”

With Varonis AI Shield, customers have always-on defense to ensure the secure use of AI, including:

• Real-time risk analysis to show you exactly which sensitive data is exposed to AI
• Automated risk remediation to continually eliminate data exposure at scale
• Behavior-based threat detection to identify abnormal or malicious behavior
• 24x7x365 alert response to investigate, contain, and stop data threats

AI security is data security. AI Shield helps employees use AI without putting data at risk, ensuring only the right people — and agents — have access to data, that use is monitored, and abuse is flagged.

Additional Resources

• Read more on the Varonis blog .
• See Varonis in action: schedule a 30-minute demo .
• Check out these Varonis integrations .
• For more information on Varonis' solution portfolio, please visit www.varonis.com .
• Visit our blog and join the conversation on X , LinkedIn , and YouTube .
  

About Varonis
Varonis (Nasdaq: VRNS) is the leader in data security, fighting a different battle than conventional cybersecurity companies. Our cloud-native Data Security Platform continuously discovers and classifies critical data, removes exposures, and detects advanced threats with AI-powered automation.

Thousands of organizations worldwide trust Varonis to defend their data wherever it lives — across SaaS, IaaS, and hybrid cloud environments. Customers use Varonis to automate a wide range of security outcomes, including data security posture management (DSPM), data classification, data access governance (DAG), data detection and response (DDR), data loss prevention (DLP), AI security, and insider risk management.

Varonis protects data first, not last. Learn more at www.varonis.com .

Investor Relations Contact:
Tim Perz
Varonis Systems, Inc.
646-640-2112
investors@varonis.com

News Media Contact:
Rachel Hunt
Varonis Systems, Inc.
877-292-8767 (ext. 1598)
pr@varonis.com

ISLANDIA, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- West Technology Group, LLC (the “Company” or “West”), a global leader in technology-enabled services, today announced the appointment of Sam Meckey as President of its WestCX business unit, effective immediately.

Mr. Meckey most recently served as the Chief Executive Officer of UpHealth, a publicly traded digital health solutions business. Mr. Meckey joined UpHealth from EXL Services, where he led the healthcare business, driving a transformation of this business from a BPO to a tech-enabled services player. Before EXL, Mr. Meckey held several positions at Optum, ultimately leading the $1B global BPO/ITO business as President. Prior to Optum, Mr. Meckey was a pilot and officer in the U.S. Navy. He earned his BS in Economics from the United States Naval Academy, an MS in Aerospace Operations from Embry-Riddle Aeronautical University, and his MBA from Harvard Business School.

WestCX delivers AI-driven omnichannel solutions that power intelligent interactions and optimize engagements, improving efficiency and customer satisfaction. WestCX includes the Company’s TeleVox and Mosaicx brands.

“I am excited to welcome Sam Meckey as WestCX’s new President. Sam brings two decades of experience in the healthcare industry and has a remarkable track record of driving sales growth, transforming businesses for sustained success, and optimizing operations. His strategic leadership and commitment to operational excellence has consistently delivered measurable results and I look forward to working with him in this next phase of WestCX’s development,” said John Shlonsky, Chief Executive Officer and President of West.

About West

West Technology Group, LLC is an innovative, cloud-based, global technology partner to clients around the world. Our solutions connect people and organizations at the right time and in the right ways, making those mission-critical connections more relevant, engaging, and actionable - turning Information to Insight.

West has sales and/or operations in the United States, Canada, Europe, Asia Pacific, and Latin America. West is controlled by affiliates of certain funds managed by Apollo Global Management, Inc. (NYSE: APO). For more information, please visit www.west.com .

MENLO PARK, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced it plans to improve on its already highly accurate methylation detection capabilities in HiFi chemistry through licensing advanced DNA methylation detection methods developed by Professor Dennis Lo and colleagues at the The Chinese University of Hong Kong (CUHK) and Centre for Novostics. The licensed technology is designed to enhance PacBio HiFi sequencing with improved detection of DNA base modifications—including 5-hydroxymethylcytosine (5hmC) and hemimethylated 5-methylcytosine (5mC)—in native DNA. PacBio plans to bring these capabilities to its Revio and Vega systems, building on its existing 5mC support to deliver even more comprehensive epigenomic insights as part of standard HiFi whole-genome sequencing workflows.

“PacBio was the first to detect native epigenetic modifications alongside accurate DNA sequencing. With the integration of the CUHK deep learning models, our technology will be able to detect many additional and biologically meaningful methylation signatures, including 5hmC and strand-specific 5mC,” said Christian Henry, President and CEO of PacBio. "Our commitment to continually improving HiFi chemistry will enable our customers to gain even deeper insights into the human genome, powering new discoveries and clinical possibilities."

The newly licensed technology includes an enhanced AI deep learning framework known as Holistic Kinetic Model 2 (HK2), which integrates convolutional and transformer layers to model local and long-range kinetic features with extraordinary precision. HK2 is designed to significantly improve the accuracy of 5mC and N6-methyladenine (6mA) detection and introduces native 5hmC calling in single molecules—a first for HiFi sequencing.

HiFi sequencing, available on both the Revio and Vega platforms, provides a comprehensive and simultaneous readout of the genome and epigenome from native DNA without the need for chemical conversion, additional sample preparation, or parallel workflows. The new capabilities from the HK2 model will be delivered to existing customers through software updates, with no changes to sequencing protocols and no additional cost.

“I am delighted to see this technology now being deployed more broadly through PacBio’s global customer base,” said Professor Dennis Lo, Scientific Director of Centre for Novostics, CUHK. “Accurate detection of DNA methylation—particularly 5mC and 5hmC—on native molecules is important for advancing research in cancer, human development, and beyond. With the improvements enabled by HK2, methylation calling with PacBio HiFi sequencing is poised to set a new standard for accuracy in the industry, surpassing other available technologies.”

CUHK, together with Take2 Technologies Limited, a Hong Kong-based biotechnology company, pioneered robust 5mC detection in 2021 using the PacBio platform. PacBio introduced on-instrument 5mC detection in April 2022 and extended support to 6mA in December 2024 for Fiber-seq chromatin architecture studies. HK2 is designed to push detection performance to new levels of accuracy. Importantly, HK2 will also enable strand-specific 5mC analysis, which opens new opportunities to study hemimethylation—an emerging epigenetic signal.

HiFi 5-base sequencing has already been adopted by pioneering institutions such as Children’s Mercy Kansas City, the first to use comprehensive genomic and epigenomic profiling in a clinical setting​. GeneDx is also leveraging this capability to investigate the diagnostic potential of epigenetic signals in neonatal care​.

The ability to profile 5hmC—a dynamic and tissue-specific epigenetic mark implicated in brain development, cancer, and neurodegenerative diseases—opens new frontiers in liquid biopsy, cancer detection, and cell-free DNA analysis​. Unlike chemical-based methods such as bisulfite or TAPS sequencing, which degrade DNA and diminish phasing and structural context, PacBio’s native detection maintains DNA integrity and supports haplotype-resolved analysis in complex genomic regions​.

The licensing of HK2 marks another milestone in PacBio’s continued leadership in long-read epigenomics. Combined with the high accuracy and long read lengths of HiFi sequencing, HK2 delivers a uniquely powerful tool for understanding the full landscape of genome function—across both sequence and modification.

"By enabling high-resolution, native detection of 5mC, 6mA, and 5hmC, we’re empowering researchers to ask more sophisticated questions and uncover new biology," said Mark Van Oene, Chief Operating Officer at PacBio. "And because this capability is powered entirely by software and existing sequencing signals, customers can access it with no added cost or workflow changes."

PacBio aims to deliver these capabilities to Revio and Vega through a future software update. For more information about HiFi chemistry, visit https://www.pacb.com/technology/hifi-sequencing/ .

About Pacific Biosciences
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

About The Chinese University of Hong Kong (CUHK)
Founded in 1963, CUHK is a leading comprehensive research university with a global reputation and world-leading rankings. Located in the heart of Asia, CUHK has a vision and a mission to combine tradition with modernity, and to bring together China and the West. The University is devoted in cutting edge research and translation of research outputs into useful products. CUHK is renowned for its leading role in molecular diagnostics research. The noninvasive prenatal diagnostic test for Down syndrome developed by Dennis Lo is widely adopted globally with more than 100 million tests performed since its inception. Centre for Novostics, an affiliate CUHK, is supported by the InnoHK initiative under the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government dedicated to molecular diagnostic research.

About Take2 Technology Limited (Take2)
Founded in 2019, Take2 is a Hong Kong-based biotechnology company. Take2 focuses on the development of novel molecular diagnostic approaches, in particular in the area of epigenetic analysis and cancer screening.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, the benefits or expected benefits of using, PacBio products or technologies, including in connection with anticipated improvements to methylation detection with respect to 5hmC, 5mC, 6mA, and strand-specific 5mC, and related opportunities for customers to gain deeper insights, power new discoveries and enable clinical possibilities with no additional cost or change to sequencing protocols; setting new standards for accuracy, and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, risks inherent in developing and commercializing new technologies; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements, including PacBio’s preliminary unaudited financial information and PacBio’s financial guidance, are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

Contacts

Investors:
Todd Friedman
ir@pacificbiosciences.com

Media:
pr@pacificbiosciences.com

FORT WORTH, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- Lottery.com Inc. (Nasdaq: LTRY, LTRYW), a leading provider of digital lottery, sweepstakes, and sports entertainment technology, today announced that it is planning its first shareholder webinar in more than three years to be held in the coming weeks as part of its continued commitment to transparency, engagement and building trust. Chairman and CEO Matthew McGahan will also be issuing a formal communication to shareholders providing insight into the Company’s strategic progress and vision for growth.

These initiatives come as the Company nears the successful conclusion of a two-year corporate turnaround, which has positioned Lottery.com for long-term operational strength, strategic expansion, and shareholder value creation.

Matthew McGahan, Chairman and CEO of Lottery.com, commented:
“As we approach the final phase of this disciplined turnaround, now is the right time to directly engage with our shareholders, share our roadmap, and outline the exciting opportunities ahead. This journey has always been about rebuilding with integrity and ambition—and we’re ready to deliver.”

A Comprehensive Turnaround from the Top Down:

• Board and Governance: Complete overhaul of the Board of Directors, installing experienced leadership committed to transparency and growth. Additionally, the Company formed a strategic Advisory Board in February 2025, comprising industry leaders and experts guiding international expansion, responsible gaming, and technological innovation.
• C-Suite Rebuild: Restructuring of the executive team, with McGahan transitioning from Non-Executive Chairman to CEO and President of both Lottery.com and Sports.com. Additionally, the Company appointed Robert Stubblefield as its Chief Financial Officer and Gregory Potts as its Chief Operating Officer.
• Legal and Compliance Reset: Replacement of all prior legal counsel, with new representation including the recent engagement of recognized Crowell & Moring as the Company’s global counsel.
• Capital Markets and Strategic Funding: Appointment of Cohen & Company Capital Markets as investment banker, alongside securing $100 million from Generating Alpha Ltd. and $150 million from United Capital Investments London (UCIL). These facilities are being deployed strategically to drive shareholder value through cash-generative acquisitions; cutting-edge technology development and investment; resumption and expansion of gaming operations that drives revenues; and building balance sheet strength.
  

Strategic Use of Funding for Growth:
The Company emphasizes that capital secured through its funding facilities, including the recently filed S-1, will be strategically deployed to:

• Build or acquire state-of-the-art technology for Lottery.com and Sports.com, enabling immersive, live-streaming sports media and enhanced fan engagement.
• Close advanced stage, revenue generative acquisitions, designed to accelerate profits and deliver shareholder value.
• Strengthen the Company’s balance sheet and fund innovation across its digital lottery and sports entertainment platforms.
  

Legal Success and Stability:

Lottery.com has successfully defended more than a dozen legal cases, eliminating key litigation risks and solidifying the foundation for future growth.

Vision for 2025 and Beyond:

With the turnaround nearly complete, the Company is focused on increasing revenues through resuming gaming operations and monetizing Sports.com and completing certain acquisitions that will accelerate profitability and shareholder value.

Engaging with Shareholders:
As part of the Lottery.com’s continued commitment to transparency, shareholder engagement and building public trust, the Company plans the following:

• Webinar: The Company shall host a shareholder webinar in Q2.
• Shareholder Letter: A formal communication from Chairman and CEO Matthew McGahan to the Company’s shareholders will be issued in the coming weeks.

Important Notice Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “initiatives,” “continue,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company’s internal accounting controls, additional examination of the preliminary conclusions of such review, the Company’s ability to secure additional capital resources, the Company’s ability to continue as a going concern, the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with the Bid Price Requirement, the Company’s ability to regain compliance with Nasdaq Listing Rules, the Company’s ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading “Risk Factors” in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.

This press release was published by a CLEAR® Verified individual.

MONTERREY, Mexico, April 28, 2025 (GLOBE NEWSWIRE) -- Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) announced today its operational and financial results for the first quarter of 2025.

• FEMSA: Total Consolidated Revenues grew 11.1% and Income from Operations increased 4.9% compared to 1Q24.
• FEMSA Retail ¹ : Proximity Americas t otal Revenues grew 6.8% and Income from operations decreased 11.8% versus 1Q24.
• SPIN: Spin by OXXO had 8.9 million active users ² representing 20.9% growth compared to 1Q24 while Spin Premia had 25.2 million active loyalty users ² representing 15.9% growth compared to 1Q24, and an average tender ³ of 42.5 % which increased from 35.1% tender in 1Q24.
• COCA-COLA FEMSA: Total Revenues and Income from Operations grew 10.0% and 7.4%, respectively against 1Q24.

José Antonio Fernandez Carbajal, FEMSA’s Chief Executive Officer, commented:

“During the first quarter, we were able to navigate a challenging environment and calendar across several markets, particularly in Mexico, taking advantage of our resilient, geographically diversified business platform, and our outstanding team. For example, Coca-Cola FEMSA leveraged solid volume performance and currency tailwinds in most of its South American markets to offset softer trends in Mexico, keeping them in a position to deliver a solid set of results for the quarter. We also saw promising performances from several of our international health retail operations, enhanced by favorable FX tailwinds as certain South American currencies strengthened against the Mexican peso.

At Proximity Americas, we had a slower start to the year. In many ways we were able to anticipate this, given the combination of an adverse calendar, a continued soft consumer environment, and a demanding comparison base, particularly at OXXO Mexico where these trends manifested themselves in the form of a decline in same-store traffic, that in turn put some pressure on the top line. We were able to mitigate this pressure with another strong showing at the gross margin level, however, we are also facing higher expenses that largely reflect increased labor costs. Accordingly, we have put in place or accelerated a broad array of top-line and cost-cutting initiatives to drive revenues and commercial income, and to mitigate the higher operating and overhead expenses.

Fortunately, we have good visibility into certain elements of our Mexico business for the rest of the year, and our base case is projecting a recovery as we approach mid-year and gaining momentum during the third quarter and beyond. Global macroeconomic uncertainty is high right now, but given what we can estimate now, and the variables that are within our control, we anticipate 2025 will turn out to be another solid year for us, particularly when we consider that the second half of the year weighs more than the first half for many of our business units. We have been through slowdowns many times before, and our businesses have demonstrated time and time again their defensive and resilient nature, and their ability to adapt and emerge from these tough periods in good, if not better, shape.

We are constructive on the initiatives being implemented across businesses, and on the multiple levers we can utilize to drive incremental revenues, lower costs, and ultimately profitability. We remain cautiously optimistic and confident that we have a powerful and resilient business platform, a solid strategy, and the best possible team to carry out the task.”

ABOUT FEMSA
FEMSA is a company that creates economic and social value through companies and institutions and strives to be the best employer and neighbor to the communities in which it operates. It participates in the retail industry through a Proximity Americas Division operating OXXO, a small-format store chain, and other related retail formats, and Proximity Europe which includes Valora, our European retail unit which operates convenience and foodvenience formats. In the retail industry it also participates though a Health Division, which includes drugstores and related activities and Spin, which includes Spin by OXXO and Spin Premia, among other digital financial services initiatives. In the beverage industry, it participates through Coca-Cola FEMSA, the largest franchise bottler of Coca-Cola products in the world by volume. Across its business units, FEMSA has more than 392,000 employees in 18 countries. FEMSA is a member of the Dow Jones Best-in-Class World Index & Dow Jones Best-in-Class MILA Pacific Alliance Index, both from S&P Global; FTSE4Good Emerging Index; MSCI EM Latin America ESG Leaders Index; S&P/BMV Total México ESG, among other indexes.

_______________________

^(A) Please refer to page 12 for our definition of “comparable” and a description of the factors affecting the comparability of our financial and operating performance.
¹ FEMSA Retail: Proximity Americas & Europe, Fuel and FEMSA Health.
² Active User for Spin by OXXO: Any user with a balance or that has transacted within the last 56 days.
Active User for Spin Premia: User that has transacted at least once with OXXO Premia within the last 90 days.
³ Tender: OXXO MXN sales with Spin Premia redemption or accrual / Total OXXO MXN Sales, during the period.

A Media Snippet accompanying this announcement is available by clicking on this link.

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, has announced a first-of-its-kind genealogy-focused partnership with Ancestry , the global leader in family history. As part of Getty Images’ HBCU Grants Program , this initiative will focus on the digital preservation and accessibility of historical documents, records and the photographic archives of Historically Black Colleges and Universities (HBCUs). Once digitized, these invaluable archives will become searchable on Ancestry websites, helping millions of people discover and connect with the rich legacy of HBCUs.

Working alongside Getty Images, Ancestry will collaborate with participating HBCUs to identify and digitize documents, such as newsletters, newspapers, bulletins, student records, school catalogues, yearbooks, directories, and photographs that are critical for digital preservation. These efforts extend an essential resource to HBCUs beyond imagery, ensuring the protection of invaluable intellectual property and proper metadata application.

Cassandra Illidge, Vice President of Global Partnerships and Executive Director of the HBCU Grants Program at Getty Images, said: “Since its launch in 2021, the HBCU Grants Program has primarily focused on preserving photography. However, during our visits to partner institutions, we recognized that our scope should be broader. Vital records and historical documents also need attention, as they significantly contribute to the important legacy of HBCUs. Our partnership with Ancestry enhances our commitment to preserving the valuable history of HBCUs and increases access, visibility, and awareness of untold stories for a global audience. By connecting students, alumni, and institutions through genealogy, we aim to create richer context for historical research and foster a deeper understanding of family history.”

Through the program, HBCUs retain full copyright ownership to their print and digitized assets and data. Ancestry will contract directly with each HBCU and work collaboratively to digitize selected materials on-site. All digital files will be delivered to the HBCUs, and complimentary, campus-wide access to Ancestry’s platform will be provided, allowing students and faculty to explore and share their family histories and search millions of primary sources available on Ancestry.

“Ancestry is proud to partner with Getty Images and HBCUs to help preserve and celebrate the rich legacies of these important institutions for generations to come,” said Head of US Content and Philanthropic Initiatives at Ancestry, Dr. Lisa Pearl. “By combining the vast archives of these historic institutions with Ancestry's cutting-edge technology, we’re protecting these important documents and opening the door for families to uncover untold stories of inspiring HBCU alumni and ancestors.”

This partnership was initiated with Lincoln University, the nation’s first degree-granting HBCU, in Pennsylvania, USA. Lincoln joined Getty Images’ HBCU Grants Program last year with hundreds of contemporary and archival photos currently available for licensing in the HBCU Collection on gettyimages.com. Ancestry has already started digitizing Lincoln’s historical documents, including the Lincolnian and deteriorating records, as well as hundreds of photographs from Lincoin’s archival collection.

A Media Snippet accompanying this announcement is available by clicking on this link.

Getty Images and Ancestry launched their partnership at Lincoln University of Pennsylvania. The companies worked alongside the Langston Hughes Memorial Library staff to discover and digitize historical documents, records and photographs from Lincoln’s historic archives which dates back to 1854. (Photos by Cassandra Illidge) Pictured: Tiffany Davis (Lincoln), Raquel Lightner (Lincoln), David Crockett (Ancestry) Not pictured: Ashley Gillard (Lincoln), Travis Primrose (Lincoln), Cassandra Illidge (Getty Images)

“We are immensely proud to partner with Getty Images and Ancestry to launch this partnership that will allow us the opportunity to not only tell the Lincoln story but also help families tell their stories of connections to the university,” said Lincoln University President Dr. Brenda A. Allen. “Combining Getty Images’ expertise in producing high-quality visuals with Ancestry’s unparalleled genealogical resources, this collaboration will enrich our educational programs, foster deeper connections to our heritage, and empower our community to explore and celebrate the rich history of our university.”

To learn more about the wider HBCU Grants Program, including the institutions working with Getty Images, additional program partners, scholarship and mentorship opportunities for students and access to the HBCU Collection, go to: https://www.gettyimages.com/corporate-responsibility/hbcu-partnership

Media Contact:
Jenna Attardi
Jenna.Attardi@gettyimages.com

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in TP53 mutated Acute Myeloid Leukemia (AML) cells are being presented in a poster session at the American Association for Cancer Research (AACR) taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL.

Patients with TP53–mutated AML continue to face extremely poor outcomes, even with intensive chemotherapy or the addition of stem cell transplantation. Preclinical data suggest that SLS009, a highly selective CDK9 inhibitor, can induce apoptosis downstream of p53 by targeting critical proteins such as MCL-1 and survivin, regardless of p53 status. Immunoblot analysis reveals near-complete removal of these proteins in treated cells within 8 hours of exposure to SLS009. Furthermore, the treatment reduced TP53-mutated leukemia cell populations by up to 97% in combination with azacitidine–venetoclax, and by up to 80% as monotherapy.

“These findings are an exciting step forward in addressing one of the most challenging subsets of AML,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “The ability of SLS009 to overcome TP-53 driven resistance in preclinical models, combined with the positive data we have seen in our ongoing Phase 2 AML program, including a response in a patient with a TP53 mutation, gives us hope that we may one day offer an effective therapeutic option to patients with AML who have long been underserved.”

SLS009 is currently in Phase 2 clinical trials in patients with relapsed or refractory (r/r) AML following venetoclax-based regimens, including patients with TP53-mutated leukemia. Recently announced data revealed that r/r AML patients receiving 30 mg of SLS009 BIW achieved a mOS of 8.8 months for all patients, while the mOS in AML myelodysplasia-related-changes (MRC) patients reached 8.9 months - far surpassing the historical benchmark of 2.5 months. Among patients with mutation ASXL1, 4/6 (67%) responded; among those with RUNX1 3/5 (60%) responded, and among those with TP53 1/3 (33%) responded. In addition, there were 3 patients with adverse karyotypes, and 1 responded.

“Over the past decade we’ve seen significant progress in the treatment of AML, particularly with the introduction of the venetoclax/azacitidine regimen, the use of targeted agents, and safer application of haploidentical stem cell transplants,” said Dr Phillip Amrein, MD, Clinical Investigator, Massachusetts General Hospital, Assistant Professor of Medicine Harvard Medical School, the senior author of the study. “Yet, leukemias characterized by TP53 remain a major area of unmet need, with poor outcomes even with bone marrow transplantation. The preclinical findings suggest that CDK9 inhibition might have the potential to overcome this resistance and restore sensitivity to existing therapies, offering a promising new path forward for high-risk patient populations.”

Poster presentation details:

Title: CDK9 inhibition enhances apoptosis of TP53 mutated AML when combined with standard chemotherapy

Session Date and Time: Monday, April 28, 20025, 9:00 AM to 12:00 noon

Session Title: CDK9 inhibition enhances apoptosis of TP53 mutated AML when combined with standard chemotherapy

Location: Poster Section 17

Poster Board #: 1626

The poster will be available on SELLAS websites following the session.

SLS009 is currently being investigated in a Phase 2 open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine, including AML patients with ASXL1 mutations. Initial clinical safety and efficacy data are available. In addition, the study aims to identify biomarkers for the target patient population and enrichment for further trials. For more information on the study, visit clinicaltrial.gov identifier NCT04588922 .

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact

Bruce Mackle

Managing Director

LifeSci Advisors, LLC

SELLAS@lifesciadvisors.com

SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced new research published in the peer-reviewed Journal of Investigative Dermatology describing the positive effects of ART26.12 in both in vitro and in vivo psoriasis models, showing results comparable to immunomodulatory drugs with known serious adverse events.

The research article, titled “ART26.12, A FATTY ACID-BINDING PROTEIN 5 INHIBITOR, SHOWS EFFICACY IN PRECLINICAL PSORIASIS MODELS,” highlights ART26.12, Artelo’s orally active, small-molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5) and its potential ability to treat psoriasis.

George Warren, PhD, Lead Author and Principal Scientist at Artelo, said, “We are excited to share the results on this novel target in psoriasis. Our findings demonstrate that ART26.12 has effects comparable to powerful immunomodulators, while its unique pharmacology leads to a significantly distinct expression of proteins and lipids in the skin.”

FABP5, sometimes referred to as epidermal FABP, was first discovered in psoriasis tissue in the early 1990s. It is highly expressed in skin and immune cells and plays a key role in skin cell homeostasis. FABP5 is upregulated in numerous dermatological conditions, promoting inflammation and correlating with disease severity.

Dr. Warren added, “Pre-clinical IND-enabling studies with ART26.12, supported by a literature review of greater than 300 studies examining FABP inhibition, imply a low toxicological risk for ART26.12, which, if borne out in clinical studies, suggest FABP5 inhibition with an orally delivered small molecule may be an attractive, less costly, and safer approach for treating this debilitating chronic disease.”

A Phase 1 Single Ascending Dose study in healthy volunteers with ART26.12 has completed enrollment with data announcements expected this quarter.

About ART26.12
ART26.12, Artelo’s lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Data from the first Phase 1 trial with ART26.12 is anticipated in Q2 2025. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.

About Psoriasis
Psoriasis is a chronic autoimmune condition that accelerates the production of skin cells, leading to the formation of red, scaly patches. Affecting about 2–3% of the global population, Psoriasis can occur anywhere on the body, most commonly on the scalp, elbows, and knees. Psoriasis is a lifelong condition, and while its severity varies, it can significantly impact quality of life through physical discomfort and emotional distress. Flare-ups are often triggered by factors such as stress, infections, or environmental changes. In addition to the visible symptoms, psoriasis is associated with a higher risk of other health issues, including cardiovascular disease. There is no cure for psoriasis, and current treatments, while broadly effective, can have significant side effects, highlighting the need for safer, more effective therapies. According to Fortune Business Insights , the global psoriasis market was estimated to be valued at $27.2 billion in 2024, and is expected to grow from $29.15 billion in 2025 to $57.68 billion by 2032.

About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and X: @ArteloBio.

Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com

IRVINE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ^® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/241,151, entitled, “Intragastric Device.” When issued, the patent will cover claims for an intragastric balloon system, comprising a swallowable capsule with a self-sealing fill valve and a degradable release valve designed to deflate and open the valve around three months after inflation with saline liquid, and configured for natural excretion after deflation, among other claim features. Once issued, the patent will provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).

“This key patent allowance marks a major milestone, significantly strengthening our intellectual property portfolio and securing broad protection for our innovative intragastric balloon system,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “Since filing our initial patent application in 2011, we have secured over 50 patents related to our intragastric balloon system. ReShape Lifesciences now boasts a robust portfolio of more than 160 patents issued and pending, encompassing a diverse array of innovative and protected technologies. Moving forward, we will continue to strengthen the protective ‘moat’ around our product portfolio, innovation pipeline, and commercialization efforts. Additionally, when appropriate, we will act decisively to protect our position through strategic, non-dilutive funding.”

About ReShape Lifesciences ^®
ReShape Lifesciences ^® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band ^® and Lap-Band ^® 2.0 Flex Systems provide minimally invasive, long-term treatment of obesity and are an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The Obalon ^® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com .

As previously announced ReShape has entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., pursuant to which ReShape has agreed to sell substantially all of its assets to Biorad (or an affiliate thereof), including ReShape’s Lap-Band ^® System, Obalon ^® Gastric Balloon System and the DBSN™ system (but excluding cash). Therefore, at the closing of the transactions contemplated by the asset purchase agreement, the Obalon ^® Gastric Balloon System will be owned by Biorad.

Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about the promise of the Obalon ^® Gastric Balloon System and the potential path to commercialization of the technology. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

CONTACTS

ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com

Investor Relations Contact:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

TERRE HAUTE, Ind., April 28, 2025 (GLOBE NEWSWIRE) -- Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”), will host a conference call on Monday, May 12, 2025, at 5:00 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2025. The Company’s results will be reported in a press release prior to the call.

Hallador’s management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions prior to the call by emailing the Company’s investor relations team, Elevate IR, at HNRG@elevate-ir.com .

Date: Monday, May 12, 2025
Time: 5:00 p.m. Eastern time
Dial-in registration link: here
Live webcast registration link: here

The conference call will also be broadcast live and available for replay in the investor relations section of the Company’s website at www.halladorenergy.com .

About Hallador Energy Company

Hallador Energy Company (Nasdaq: HNRG) is a vertically-integrated Independent Power Producer (IPP) based in Terre Haute, Indiana. The Company has two core businesses: Hallador Power Company, LLC, which produces electricity and capacity at its one-Gigawatt (GW) Merom Generating Station, and Sunrise Coal, LLC, which produces and supplies fuel to the Merom Generating Station and other companies. To learn more about Hallador, visit the Company’s website at www.halladorenergy.com .

Company Contact

Marjorie Hargrave
Chief Financial Officer
MHargrave@halladorenergy.com

Investor Relations Contact

Sean Mansouri, CFA
Elevate IR
(720) 330-2829
HNRG@elevate-ir.com

ESCONDIDO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (“OSS” or the “Company”) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, announced today that the Company will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. A webcast and conference call will be held that same day at 10:00 a.m. ET to review the Company’s results.

Conference Call and Webcast

Domestic: 1-800-717-1738
International: 1-646-307-1865
Conference ID: 57745 (required for entry)
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1710966&tp_key=28a1f0fc7f

Conference Call Replay

Domestic: 1-844-512-2921
International: 1-412-317-6671
Passcode: 1157745

A replay of the call will be available after 1:00 p.m. ET on May 7, 2025, through May 21, 2025.

About One Stop Systems
One Stop Systems, Inc. (Nasdaq: OSS) is a leader in AI enabled solutions for the demanding 'edge'. OSS designs and manufactures Enterprise Class compute and storage products that enable rugged AI, sensor fusion and autonomous capabilities without compromise. These hardware and software platforms bring the latest data center performance to harsh and challenging applications, whether they are on land, sea or in the air.

OSS products include ruggedized servers, compute accelerators, flash storage arrays, and storage acceleration software. These specialized compact products are used across multiple industries and applications, including autonomous trucking and farming, as well as aircraft, drones, ships and vehicles within the defense industry.

OSS solutions address the entire AI workflow, from high-speed data acquisition to deep learning, training and large-scale inference, and have delivered many industry firsts for industrial OEM and government customers.

As the fastest growing segment of the multi-billion-dollar edge computing market, AI enabled solutions require-and OSS delivers-the highest level of performance in the most challenging environments without compromise.

OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com . You can also follow OSS on X , YouTube , and LinkedIn .

Forward-Looking Statements
One Stop Systems cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by One Stop Systems or its partners that any of our plans or expectations will be achieved. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in our business, including risks described in our prior press releases and in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our latest Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Media Contacts:
Robert Kalebaugh
One Stop Systems, Inc.
Tel (858) 518-6154
Email contact

Investor Relations:
Andrew Berger
Managing Director
SM Berger & Company, Inc.
Tel (216) 464-6400
Email contact

Providence, RI, April 28, 2025 (GLOBE NEWSWIRE) -- Beeline Loans, Inc., a wholly-owned subsidiary of Beeline Holdings (NASDAQ: BLNE) a tech-forward mortgage originator focused on delivering fast, flexible financing solutions, today announced a strategic partnership with Rabbu, a leading short-term rental (STR) analytics platform used by over one million investors. The partnership creates a streamlined pipeline for investors—from identifying STR properties to securing tailored financing—all in one ecosystem.

Rabbu’s free Airbnb calculator allows users to enter any U.S. property address to receive data-driven projections, including estimated annual revenue, average daily rates, and expected occupancy. Now, with integrated access to Beeline’s investment property loans, users can move directly from analysis to action.

“This partnership expands our reach into one of the most dynamic segments in residential real estate,” said Nick Liuzza, CEO of Beeline. “We’re connecting the dots—discovery, funding, and ultimately, management—to deliver a truly frictionless STR investment experience.”

Beeline’s investment lending business has seen significant growth over the past 12 months. In 2024, more than half of its loan volume was dedicated to investment properties, with STR financing emerging as a leading driver. The company supports a full spectrum of borrower profiles through its DSCR, bank statement, and conventional loan products—all optimized for speed and simplicity.

The Rabbu partnership complements Beeline’s existing collaboration with Red Awning, a full-service STR management platform. Together, the trio forms a powerful, end-to-end solution: identify with Rabbu, finance with Beeline, manage with Red Awning.

Beeline also announced during its recent earnings call that April is expected to be its strongest revenue month since the market downturn, with increased investor demand and product diversification contributing to the momentum.

About Beeline

Beeline Financial Holdings, Inc. is a trailblazing mortgage fintech transforming the way people access property financing. Through its fully digital, AI-powered platform, Beeline delivers a faster, smarter path to home loans—whether for primary residences or investment properties. Headquartered in Providence, Rhode Island, Beeline is reshaping mortgage origination with speed, simplicity, and transparency at its core. The company is a wholly owned subsidiary of Beeline Holdings and also operates Beeline Labs, its innovation arm focused on next-generation lending solutions.

About Rabbu

Rabbu helps real estate investors find and evaluate high-performing short-term rental properties. It offers revenue estimates, ROI insights, and market data tools to analyze both on-market and off-market deals. Users can explore listings, connect with agents and lenders, and make informed investment decisions—all through a streamlined platform focused on Airbnb-style rental income.

To learn more about Beeline’s innovative financing for investment properties, visit makeabeeline.com . To explore high-performing short-term rental opportunities, visit rabbu.com .

For more information, please contact Beeline at IR@Makeabeeline.com .

DUBLIN, Ohio, April 28, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (Nasdaq: AIRE) (“reAlpha” or the “Company”), a real estate technology company developing and commercializing artificial intelligence (“AI”) technologies, is pleased to announce the appointment of Cristol Rippe as Chief Marketing Officer, effective immediately. In this role, Ms. Rippe will oversee and expand all aspects of brand, marketing, and communications of the Company, reporting directly to the Company’s President and Chief Operating Officer, Mike Logozzo.

Ms. Rippe brings over 20 years of experience building and scaling high-growth organizations in the fintech and real estate sectors. Most recently, she served as Chief Marketing Officer at Landed, a mission-driven fintech that helped essential professionals access homeownership. There, she led the company’s go-to-market strategy, expanding services nationally and more than doubling both the business-to-business and business-to-consumer pipelines. Prior to Landed, she was the founding marketing leader at Root Insurance, where she built and led the marketing team through rapid scale-up, helping the company grow to over $600 million in annual written premiums. At Root, she drove more than 500% YoY growth and led a full-funnel marketing strategy that dramatically increased brand awareness and drove rapid, sustainable growth. She also played a key role in Root’s successful IPO in October 2020, further demonstrating her ability to build brand equity and deliver results in high-stakes environments.

“Cristol’s arrival marks an exciting new chapter for the reAlpha executive team,” said Mike Logozzo, President and Chief Operating Officer of reAlpha. “Her proven ability to drive growth, elevate brand presence, and scale marketing functions aligns directly with our mission to simplify homebuying through AI. Cristol brings both strategic vision and operational expertise, and her leadership is already making a strong contribution to our organization.”

Ms. Rippe’s appointment comes after reAlpha’s announcement of a media-for-equity deal with Mercurius Media Capital in March of this year, worth $5 million. Under the terms of the agreement, reAlpha gains access to Mercurius’ media expertise and U.S. multi-channel media partners on a media credits to equity basis. Ms. Rippe will help refine reAlpha’s brand messaging and capitalize on the Mercurius arrangement to grow reAlpha’s brand awareness.

“reAlpha is redefining how people buy and finance homes, and I’m incredibly honored to join at this inflection point,” said Ms. Rippe. “The combination of AI, real estate, and consumer-first innovation is rare and powerful. I look forward to helping unlock reAlpha’s next phase of growth.”

About reAlpha Tech Corp.

reAlpha Tech Corp. (Nasdaq: AIRE) is a real estate technology company developing an end-to-end commission-free homebuying platform. Utilizing the power of AI and an acquisition-led growth strategy, reAlpha’s goal is to offer a more affordable, streamlined experience for those on the journey to homeownership. For more information, visit www.realpha.com .

Forward-Looking Statements
The information in this press release includes “forward-looking statements”. Forward-looking statements include, among other things, statements about the appointment of Ms. Rippe as Chief Marketing Officer and the anticipated benefits thereof. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: reAlpha’s limited operating history and that reAlpha has not yet fully developed its AI-based technologies; reAlpha’s ability to commercialize its developing AI-based technologies; whether reAlpha’s technology and products will be accepted and adopted by its customers and intended users; reAlpha’s ability to integrate the business of its acquired companies into its existing business and the anticipated demand for such acquired companies’ services; reAlpha’s ability to successfully enter new geographic markets; reAlpha’s ability to obtain the necessary regulatory and legal approvals to expand into additional U.S. states and maintain, or obtain, brokerage licenses in such states; reAlpha’s ability to generate additional sales or revenue from having access to, or obtaining, additional U.S. states brokerage licenses; reAlpha’s inability to accurately forecast demand for short-term rentals, corporate relocation programs and AI-based real estate focused products; the inability to execute business objectives and growth strategies successfully or sustain reAlpha’s growth; the inability of reAlpha’s customers to pay for reAlpha’s services; changes in applicable laws or regulations, and the impact of the regulatory environment and complexities with compliance related to such environment; and other risks and uncertainties indicated in reAlpha’s SEC filings. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. Although reAlpha believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. reAlpha’s future results, level of activity, performance or achievements may differ materially from those contemplated, expressed or implied by the forward-looking statements, and there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking statements. For more information about the factors that could cause such differences, please refer to reAlpha’s filings with the SEC. Readers are cautioned not to put undue reliance on forward-looking statements, and reAlpha does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:
Adele Carey, VP of Investor Relations
investorrelations@realpha.com

Media Contact:
Fatema Bhabrawala, Director of Media Relations
FBHabrawala@allianceadvisors.com

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Brag House Holdings, Inc. (NASDAQ: TBH) (the “Company” or “Brag House” ) , the premier Gen Z engagement platform at the intersection of gaming, college sports, and social interaction, today announced a strategic partnership with Florida Gator Athletics and Learfield’s Florida Gators Sports Properties, the media and technology company powering college athletics at over 200 schools. All Gators Athletics sponsorship agreements are managed by athletic media rights holder Florida Gators Sports Properties. This collaboration introduces a first-of-its-kind digital sports medium for Gen Z—reimagining how students and fans engage with college sports through gaming across the nation.

The initiative debuts with the Orange and Blue at the University of Florida (UF) , with the launch of the Brag Gator Gauntlet —a flagship series of digital and in-person gaming activations that fuse school spirit, gaming culture, and live sports into immersive, competitive experiences. These events align with real-world sports calendars, offering students and fans new, interactive ways to rally around their favorite teams through video games they already love to play.

“We’re not just adding gaming to sports—we’re creating a new lane that lives in harmony with college athletics,” said Lavell Juan Malloy II, CEO & Co-Founder of Brag House. “Starting this series with the Florida Gators and Learfield’s unparalleled access to over 200 universities allows us to scale this vision while giving brands an authentic way to connect with the most elusive and influential demographic—Gen Z.”

“This partnership represents an exciting evolution in how partners engage with the student body and Gator Nation,” said Darren McPhail, General Manager of Florida Gators Sports Properties. “By integrating gaming into our athletic culture, we’re providing innovative avenues for student involvement and offering brands a new way to engage with the younger demographics of Gator Nation.”

Redefining Fan Engagement
The Brag House x Gators Athletics initiative, in partnership with Learfield, builds a parallel sports engagement channel tailored for digitally native students:

• Interactive in-person and online gaming activations tied to real-life sporting events
• Branded gaming experiences designed to mirror student rivalries and fandom
• Name, Image, and Likeness (“NIL”)-integrated gaming content featuring student-athletes to elevate school pride and authenticity
  

Scalable Brand Opportunities

For brands seeking to connect with Gen Z in a meaningful way, this partnership delivers unrivaled access to hyper-engaged college communities:

• Custom advertising and sponsorship opportunities across digital platforms, on-site events, and athletic venues
• Gamified experiences and branded loyalty systems that reward participation and foster deeper brand affinity
• Student-athletes influencer-driven campaigns featuring serialized content
  

This monetization model shows how brands can generate a measurable return on investment while deepening engagement with target audiences.

Actionable Gen Z Insights
Beyond engagement, Brag House will continue to build a robust data engine to help brands connect with Gen Z in a more authentic and measurable way . Using proprietary behavioral data and insights, Brag House will empower marketers to create hyper-personalized, performance-optimized campaigns tailored to Gen Z’s preferences and behavior.

What’s Next
Following the first activation with Gators Athletics for students of the University of Florida, Brag House and Learfield aim to roll out the model across additional campuses later this year. The roadmap targets a 10-school expansion in 2025 , scaling to 50 campuses by the end of 2026 , supported by evolving technology capabilities and advanced audience segmentation tools.

“This is not a niche campaign—it’s a new tradition,” added Malloy. “We're defining how Gen Z connects with college athletics—and giving brands a meaningful way to be part of that story.”

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. These statements are subject to uncertainties and risks, including, but not limited to, the risk factors discussed in the “Risk Factors” section of the Company’s filings with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov . The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law.

About Brag House
Brag House is a leading media technology gaming platform dedicated to transforming casual college gaming into a vibrant, community-driven experience. By seamlessly merging gaming, social interaction, and cutting-edge technology, the Company provides an inclusive and engaging environment for casual gamers while enabling brands to authentically connect with the influential Gen Z demographic. The platform offers live-streaming capabilities, gamification features, and custom tournament services, fostering meaningful engagement between users and brands. For more information, please visit www.braghouse.com.

About Learfield
Learfield is the leading media and technology company powering college athletics. Through its digital and physical platforms, Learfield owns and leverages a deep data set and relationships in the industry to drive revenue, growth, brand awareness, and fan engagement for brands, sports, and entertainment properties. With ties to over 1,200 collegiate institutions and over 12,000 local and national brand partners, Learfield’s presence in college sports and live events delivers influence and maximizes reach to target audiences. With solutions for a 365-day, 24/7 fan experience, Learfield enables schools and brands to connect with fans through licensed merchandise, game ticketing, donor identification for athletic programs, exclusive custom content, innovative marketing initiatives, NIL solutions, and advanced digital platforms. Since 2008, it has served as title sponsor for the acclaimed Learfield Directors’ Cup, supporting athletic departments across all divisions.

Media Contact:
Fatema Bhabrawala
Director of Media Relations
fbhabrawala@allianceadvisors.com

Investor Relations Contact:
Adele Carey
VP, Investor Relations
ir@thebraghouse.com

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.

Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI1cddc009ba2b427a81ea445f5669adff
Once registered, a dial-in number, unique pin, and instructions will be provided to participants.

The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/ . A recording of the call will be available on the Company’s website following the completion of the call.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.

Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

Please visit www.iradimed.com for more information.

Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com

EAU CLAIRE, Wis., April 28, 2025 (GLOBE NEWSWIRE) -- Citizens Community Bancorp, Inc. (the “Company”) (Nasdaq: CZWI), the parent company of Citizens Community Federal N.A. (the “Bank” or “CCFBank”), today reported earnings of $3.2 million and earnings per diluted share of $0.32 for the first quarter ended March 31, 2025, compared to $2.7 million and earnings per diluted share of $0.27 for the fourth quarter ended December 31, 2024, and $4.1 million and $0.39 earnings per diluted share for the quarter ended March 31, 2024, respectively.

The Company’s first quarter 2025 operating results reflected the following changes from the fourth quarter of 2024: (1) decrease in net interest income of $0.1 million as two fewer days in the quarter were largely offset by an increase in the net interest margin of 6 basis points; (2) a smaller negative provision for credit losses of $0.3 million compared to $0.5 million in the fourth quarter; (3) higher non-interest income of $0.6 million primarily due to $0.5 million higher gain on sale of loans and $0.3 million higher net gains on sale of equity securities in the first quarter of 2025; and (4) lower non-interest expense primarily due to lower compensation and related benefits of $0.2 million and lower losses on repossessed assets of $0.2 million.

Book value per share improved to $18.02 at March 31, 2025, compared to $17.94 at December 31, 2024, and $16.61 at March 31, 2024. Tangible book value per share (non-GAAP) ¹ was $14.79 at March 31, 2025, compared to $14.69 at December 31, 2024, and a 10.1% increase from $13.43 at March 31, 2024. For the first quarter of 2025, tangible book value was positively impacted by (1) net income, (2) the impact of lower long-term interest rates which decreased the net unrealized loss on the available for sale securities portfolio, and (3) amortization of intangibles which were largely offset by the payment of the annual $0.36 per share dividend. Stockholders’ equity as a percentage of total assets was 10.12% at March 31, 2025, compared to 10.24% at December 31, 2024. Tangible common equity (“TCE”) as a percent of tangible assets (non-GAAP) ¹ decreased modestly to 8.45% at March 31, 2025, compared to 8.54% at December 31, 2024, largely due to the payment of the dividend.

“I am pleased with results in a quarter that is seasonally the slowest for us because of winter. The balance sheet is well positioned for the remainder of 2025 with strong capital and liquidity positions, strong ACL reserves and credit metrics in our historical range. Our TCE at 8.5% provides a cushion for uncertainty like we have seen thus far in 2025 and for share repurchases. Our liquidity position, including the loan to deposit ratio below 90% is expected to support quality, well priced loan growth in the low to mid-single digit percentages with strategic, relationship borrowers. Our markets remain stable with unemployment below national averages and tariff exposure appears to be indirect should this risk persist. We believe loan repricing and originations will benefit our net-interest margin expansion, especially in the second half of 2025, and throughout 2026, as well as will the impact of deposit repricing,” stated Stephen Bianchi, Chairman, President, and Chief Executive Officer.

March 31, 2025, Highlights:

• Quarterly earnings were $3.2 million, or $0.32 per diluted share for the quarter ended March 31, 2025, an increase compared to earnings of $2.7 million, or $0.27 per diluted share for the quarter ended December 31, 2024, and a decrease from $4.1 million, or $0.39 per diluted share for the quarter ended March 31, 2024.
  
  
• Net interest income decreased $0.1 million to $11.6 million for the current quarter ended March 31, 2025, from $11.7 million for the quarter ended December 31, 2024, and from $11.9 million for the quarter ended March 31, 2024. The decrease in net interest income from the fourth quarter of 2024 was primarily due to two fewer days in the quarter which was mostly offset by an increase in net interest margin of six basis points.
  
  
• The net interest margin increased to 2.85%, primarily due to lower deposit costs. The net interest margin increase in the first quarter of 2025 was negatively impacted by three basis points from lower deferred fee accretion compared to the fourth quarter of 2024 due to lower payoffs in the first quarter of 2025.
  
  
• Negative provision for credit losses of $0.25 million, $0.45 million, and $0.80 million were recorded during the quarters ended March 31, 2025, December 31, 2024, and March 31, 2024, respectively. The first quarter’s negative provision was due to decreases in on-balance sheet allowance for credit losses (“ACL”) of $0.35 million partially offset by a $0.10 million increase in off-balance sheet ACL due to an increase in unfunded loan commitments.
  
  
• Non-interest income increased by $0.6 million in the first quarter of 2025 to $2.6 million from $2.0 million the prior quarter due to $0.5 million of higher gain on sale of loans, $0.3 million of higher net gains on equity securities partially offset by lower loan fees and service charges of $0.2 million due to lower customer activity. Total non-interest income for the quarter ended March 31, 2025, was $0.7 million lower than first quarter 2024 primarily due to lower gain on sale of loans and net realized gains on debt securities.
  
  
• Non-interest expense decreased $0.3 million to $10.5 million from $10.8 million for both the fourth quarter of 2024 and the first quarter of 2024. The $0.3 million decrease in non-interest expense compared to the linked quarter was largely due to lower compensation due to lower incentive costs and lower losses on repossessed assets, partially offset by higher other expense. The $0.3 million decrease from the first quarter of 2024 was due to a $0.4 million decrease in other expenses resulting from lower SBA recourse reserve expense.
  
  
• Loans receivable decreased $16.3 million during the first quarter ended March 31, 2025, to $1.353 billion compared to the prior quarter end, largely due to the seasonal impact of lower activity.
  
  
• Total deposits increased $35.5 million during the quarter ended March 31, 2025, to $1.524 billion. Total deposit growth reflected the seasonal growth in municipal deposits of $20.8 million, which typically decreases in the middle two quarters before increasing in the fourth quarter. Growth in retail and commercial areas was partially offset by the reduction of $6.3 million in wholesale deposits due to reduction in brokered deposits.
  
  
• The last remaining Federal Home Loan Bank advance was repaid in the quarter, resulting in no advances at March 31, 2025, down from $5.0 million at December 31, 2024, and $39.5 million one year earlier.
  
  
• The effective tax rate was 19.6% for the quarter ended March 31, 2025, compared to 19.5% for the quarter ended December 31, 2024, and 21.3% for the quarter ended March 31, 2024.
  
  
• Nonperforming assets increased $0.3 million during the quarter to $14.5 million at March 31, 2025, compared to $14.2 million at December 31, 2024.
  
  
• Special mention loans increased $6.5 million to $15.0 million at March 31, 2025, from $8.5 million in the previous quarter. The increase was largely due to one C&I relationship that showed weaker cash flow than expected.
  
  
• The efficiency ratio was 73% for the quarter ended March 31, 2025, compared to 76% for the quarter ended December 31, 2024.
  

Balance Sheet and Asset Quality

Total assets increased by $31.4 million during the quarter to $1.780 billion at March 31, 2025.

Cash increased $50.0 million due to the growth in deposits and loan shrinkage growing our balances at the Federal Reserve.

Securities available for sale (“AFS”) decreased $3.2 million during the quarter ended March 31, 2025, to $139.6 million from $142.9 million at December 31, 2024. The decrease was due to principal repayments of $2.6 million, and a corporate debt security maturity of $2.5 million, partially offset by lower pre-tax unrealized losses of $1.9 million.

Securities held to maturity (“HTM”) decreased $1.2 million to $84.3 million during the quarter ended March 31, 2025, from $85.5 million at December 31, 2024, due to principal repayments.

The on-balance sheet liquidity ratio, which is defined as the fair market value of AFS and HTM securities that are not pledged and cash on deposit with other financial institutions, was 14.38% of total assets at March 31, 2025, compared to 11.75% at December 31, 2024. On-balance sheet liquidity collateralized new borrowing capacity and uncommitted federal funds borrowing availability was $852 million, or 314%, of uninsured and uncollateralized deposits at March 31, 2025, and $725 million, or 273%, at December 31, 2024.

Loans receivable decreased $16.3 million during the first quarter ended March 31, 2025, to $1.353 billion compared to the prior quarter end, largely due to the seasonal impact of lower origination and funding activity.

The office loan portfolio consisting of seventy-two loans totaled $28 million at March 31, 2025, compared to seventy-one loans totaling $28 million at December 31, 2024. Criticized loans in the office loan portfolio for the quarter ended March 31, 2025, totaled $0.5 million, the same amount at December 31, 2024, and there have been no charge-offs in the trailing twelve months.

The allowance for credit losses on loans decreased by $0.34 million to $20.2 million at March 31, 2025, representing 1.49% of total loans receivable compared to 1.50% of total loans receivable at December 31, 2024. For the quarter ended March 31, 2025, the Bank recorded a negative provision of $0.25 million which included a negative provision on ACL for loans of $0.35 million, partially offset by a provision of $0.10 million on ACL for unfunded commitments due to an increase in unfunded commitments. 30-89 day loan delinquencies decreased to 0.15% of total loans at March 31, 2025, compared to a 0.33% delinquency ratio at December 31, 2024. The Bank had $0.007 million of net recoveries in the first quarter.

Allowance for Credit Losses (“ACL”) - Loans Percentage

(in thousands, except ratios)

In addition to the ACL - Loans, the Company has established an ACL - Unfunded Commitments of $0.435 million at March 31, 2025, $0.334 million at December 31, 2024, and $0.975 million at March 31, 2024, classified in other liabilities on the consolidated balance sheets.

Allowance for Credit Losses - Unfunded Commitments:
(in thousands)

Special mention loans increased by $6.5 million to $15.0 million at March 31, 2025, compared to $8.5 million at December 31, 2024. The increase was largely due to one C&I relationship as noted earlier.

Substandard loans increased by $0.7 million to $19.6 million at March 31, 2025, compared to $18.9 million at December 31, 2024.

Nonperforming assets increased modestly by $0.3 million to $14.5 million at March 31, 2025, compared to $14.2 million at December 31, 2024.

Deposit Portfolio Composition
(in thousands)

At March 31, 2025, the deposit portfolio composition was 56% consumer, 28% commercial, 14% public, and 2% wholesale deposits compared to 57% consumer, 28% commercial, 13% public, and 2% wholesale deposits at December 31, 2024.

Deposit Composition By Type
(in thousands)

Uninsured and uncollateralized deposits were $271.7 million, or 18% of total deposits, at March 31, 2025, and $265.4 million, or 18% of total deposits, at December 31, 2024. Uninsured deposits alone at March 31, 2025, were $444.4 million, or 29% of total deposits, and $428.0 million, or 29% of total deposits at December 31, 2024.

The last remaining Federal Home Loan Bank advance was repaid in the quarter, resulting in no advances at March 31, 2025, down from $5.0 million at December 31, 2024, and $39.5 million one year earlier.

No common stock was repurchased in the first quarter of 2025. There are 238 thousand shares remaining available to repurchase under the July 2024 Board of Director repurchase authorization.

Review of Operations

Net interest income decreased $0.1 million for the quarter ended March 31, 2025, to $11.6 million from $11.7 million for the quarter ended December 31, 2024, and decreased $0.3 million from $11.9 million for the quarter ended March 31, 2024. The decrease in net interest income compared to the fourth quarter of 2024 was primarily due to two fewer days of interest income or approximately $0.2 million, the impact of smaller average assets of $0.2 million, offset by an increase in net interest margin of six basis points or $0.3 million. The net interest margin increase was negatively impacted by 3 basis points due to lower deferred fee accretion compared to the fourth quarter resulting from lower loan payoffs.

Net interest income and net interest margin analysis:
(in thousands, except yields and rates)

The table below shows the impact of certificate, loan and securities contractual fixed rate maturing and repricing.

Portfolio Contractual Repricing:
(in millions, except yields)

Non-interest income increased by $0.6 million in the first quarter of 2025, to $2.6 million from $2.0 million the prior quarter due to $0.5 million of higher gain on sale of loans and $0.3 million of higher net gains on equity securities. Total non-interest income for the quarter ended March 31, 2025, was $0.7 million lower than first quarter 2024 primarily due to lower gain on sale of loans and net realized gains on debt securities.

Non-interest expense decreased $0.3 million to $10.5 million from $10.8 million for both the previous quarter and the quarter one year earlier. The $0.3 million decrease in non-interest expense compared to the linked quarter was largely due to lower compensation due to lower incentive costs and lower losses on repossessed assets. The $0.3 million decrease from the first quarter of 2024 was largely due to a $0.4 million decrease in other expense due to lower SBA recourse reserve expense.

Provision for income taxes increased to $0.8 million in the first quarter of 2025, from $0.7 million in the fourth quarter of 2024, largely due to higher pre-tax income. The effective tax rate was 19.6% for the quarter ended March 31, 2025, 19.5% for the quarter ended December 31, 2024, and 21.3% for the quarter ended March 31, 2024.

These financial results are preliminary until the Form 10-Q is filed in May 2025.

About the Company

Citizens Community Bancorp, Inc. (NASDAQ: “CZWI”) is the holding company of the Bank, a national bank based in Altoona, Wisconsin, currently serving customers primarily in Wisconsin and Minnesota through 21 branch locations. Its primary markets include the Chippewa Valley Region in Wisconsin, the Twin Cities and Mankato markets in Minnesota, and various rural communities around these areas. The Bank offers traditional community banking services to businesses, ag operators and consumers, including residential mortgage loans.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this release are considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using forward-looking words or phrases such as “anticipate,” “believe,” “could,” “expect,” “estimates,” “intend,” “may,” “on pace,” “preliminary,” “planned,” “potential,” “should,” “will,” “would” or the negative of those terms or other words of similar meaning. Such forward-looking statements in this release are inherently subject to many uncertainties arising in the operations and business environment of the Company and the Bank. These uncertainties include: conditions in the financial markets and economic conditions generally; the impact of inflation on our business and our customers; geopolitical tensions, including current or anticipated impact of military conflicts; higher lending risks associated with our commercial and agricultural banking activities; future pandemics (including new variants of COVID-19); cybersecurity risks; adverse impacts on the regional banking industry and the business environment in which it operates; interest rate risk; lending risk; changes in the fair value or ratings downgrades of our securities; the sufficiency of allowance for credit losses; competitive pressures among depository and other financial institutions; disintermediation risk; our ability to maintain our reputation; our ability to maintain or increase our market share; our ability to realize the benefits of net deferred tax assets; our ability to obtain needed liquidity; our ability to raise capital needed to fund growth or meet regulatory requirements; our ability to attract and retain key personnel; our ability to keep pace with technological change; prevalence of fraud and other financial crimes; the possibility that our internal controls and procedures could fail or be circumvented; our ability to successfully execute our acquisition growth strategy; risks posed by acquisitions and other expansion opportunities, including difficulties and delays in integrating the acquired business operations or fully realizing the cost savings and other benefits; restrictions on our ability to pay dividends; the potential volatility of our stock price; accounting standards for credit losses; legislative or regulatory changes or actions, or significant litigation, adversely affecting the Company or Bank; public company reporting obligations; changes in federal or state tax laws; and changes in accounting principles, policies or guidelines and their impact on financial performance. Stockholders, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Such uncertainties and other risks that may affect the Company’s performance are discussed further in Part I, Item 1A, “Risk Factors,” in the Company’s Form 10-K, for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 13, 2025 and the Company’s subsequent filings with the SEC. The Company undertakes no obligation to make any revisions to the forward-looking statements contained in this news release or to update them to reflect events or circumstances occurring after the date of this release.

¹ Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, such as net income as adjusted, net income as adjusted per share, tangible book value, tangible book value per share, tangible common equity as a percent of tangible assets and return on average tangible common equity, which management believes may be helpful in understanding the Company’s results of operations or financial position and comparing results over different periods.

Net income as adjusted and net income as adjusted per share are non-GAAP measures that eliminate the impact of certain expenses such as branch closure costs and related severance pay, accelerated depreciation expense and lease termination fees, and the gain on sale of branch deposits and fixed assets. Tangible book value, tangible book value per share, tangible common equity as a percentage of tangible assets and return on average tangible common equity are non-GAAP measures that eliminate the impact of goodwill and intangible assets on our financial position. Management believes these measures are useful in assessing the strength of our financial position.

Where non-GAAP financial measures are used, the comparable GAAP financial measure, as well as the reconciliation to the comparable GAAP financial measure, can be found in this press release. These disclosures should not be viewed as a substitute for operating results determined in accordance with GAAP, nor are they necessarily comparable to non-GAAP performance measures that may be presented by other banks and financial institutions.

Contact: Steve Bianchi, CEO
(715)-836-9994

(CZWI-ER)

Note: Certain items previously reported were reclassified for consistency with the current presentation.

Reconciliation of GAAP Net Income and Net Income as Adjusted (non-GAAP)

(in thousands, except per share data)

(1) Branch closure costs include severance pay recorded in compensation and benefits and depreciation and right of use lease asset accelerated expense included in other non-interest expense in the consolidated statement of operations.
(2) Pretax income as adjusted and net income as adjusted are non-GAAP measures that management believes enhances the market’s ability to assess the underlying business performance and trends related to core business activities.
(3) Provision for income tax on net income as adjusted is calculated at our effective tax rate for each respective period presented.

Loan Composition

(in thousands)

Nonperforming Assets
Loan Balances at Amortized Cost

(in thousands, except ratios)

Average Balances, Interest Yields and Rates

(in thousands, except yields and rates)

Wholesale Deposits
(in thousands)

Key Financial Metric Ratios:

Reconciliation of Return on Average Assets

(in thousands, except ratios)

(1) See Reconciliation of GAAP Net Income and Net Income as Adjusted (non-GAAP)

Reconciliation of Return on Average Equity

(in thousands, except ratios)

(1) See Reconciliation of GAAP Net Income and Net Income as Adjusted (non-GAAP)

Reconciliation of Return on Average Tangible Common Equity (non-GAAP)

(in thousands, except ratios)

Reconciliation of Efficiency Ratio

(in thousands, except ratios)

Reconciliation of tangible book value per share (non-GAAP)

(in thousands, except per share data)

Reconciliation of tangible common equity as a percent of tangible assets (non-GAAP)

(in thousands, except ratios)

¹ Net income as adjusted and net income as adjusted per share are non-GAAP financial measures that management believes enhances investors’ ability to understand the underlying business performance and trends related to core business activities. For a detailed reconciliation of GAAP to non-GAAP results, see the accompanying financial table “Reconciliation of GAAP Net Income and Net Income as Adjusted (non-GAAP)”.

² Return on average assets as adjusted is a non-GAAP measure that management believes enhances investors’ ability to understand the underlying business performance and trends relative to average assets. For a detailed reconciliation of GAAP to non-GAAP results, see the accompanying financial table “Reconciliation of Return on Average Assets as Adjusted (non-GAAP)”.

³ Return on average equity as adjusted is a non-GAAP measure that management believes enhances investors’ ability to understand the underlying business performance and trends relative to average equity. For a detailed reconciliation of GAAP to non-GAAP results, see the accompanying financial table “Reconciliation of Return on Average Equity as Adjusted (non-GAAP)”.

⁴ Tangible book value, tangible book value per share, tangible common equity as a percent of tangible assets and return on tangible common equity are non-GAAP measures that management believes enhances investors’ ability to understand the Company’s financial position. For a detailed reconciliation of GAAP to non-GAAP results, see the accompanying financial table “Reconciliation of tangible book value per share (non-GAAP)”, “Reconciliation of tangible common equity as a percent of tangible assets (non-GAAP)”, and “Reconciliation of return on average tangible common equity)”.

SOMERSET, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- CompoSecure, Inc. (“CompoSecure”) (NASDAQ: CMPO) , a leader in metal payment cards, security, and authentication solutions, in collaboration with Baanx and MetaMask, today announced the launch of the MetaMask metal payment card. The new cutting-edge payment solution bridges the gap between self-custody crypto and real-world spending. This metal card enables users to securely pay directly from their self-custody MetaMask wallets, eliminating the need for traditional banking intermediaries. MetaMask previewed the new card at ETHDenver last month, and is set to launch worldwide in the second quarter of 2025.

"The future of non-custodial neobanking is here,” said Simon Jones, Chief Commercial Officer at Baanx. “Our partnership with MetaMask and Mastercard will make spending crypto as easy as tap-to-pay. No conversions, no delays, no middlemen, just seamless, instant transactions. From inspiration to security technology, the team at CompoSecure made our dreams a reality, creating this beautifully designed metal payment card.”

Backed by Mastercard’s global payment network, the MetaMask Card transforms crypto into a seamless payment tool. The MetaMask card seamlessly bridges the gap between Web2 and Web3 ecosystems like a traditional debit card, enabling users to purchase directly from their MetaMask wallet while retaining custody of their funds until the moment of the transaction. Whether grabbing coffee, booking a flight, or paying rent, crypto holders can now spend their digital assets instantly without conversions, delays, or hidden fees. The new metal payment card solves “the last mile” problem with a simple, secure, and direct way to spend directly from one of the world's leading self-custody wallet providers.

"For too long, crypto users have been locked out of everyday finance,” said Ale Machado, Product Manager at MetaMask. “The MetaMask Card changes that. It allows millions of users worldwide to finally bridge the gap between the blockchain and the real world without sacrificing control or security."

Unlike traditional crypto debit cards, the MetaMask Card doesn’t require users to pre-load funds or convert crypto into fiat before spending. Instead, a smart contract seamlessly verifies and authorizes transactions on the blockchain in under five seconds, ensuring instant payment processing. This non- custodial neo-banking model ensures users retain full control of their digital assets, avoiding the risks associated with centralized exchanges or third-party financial institutions. The card operates on the Linea network, secured by Ethereum, enabling fast and cost-effective transactions on a truly global scale.

“The MetaMask metal payment card isn’t just another crypto card, it’s a paradigm shift,” said Jon Wilk, CEO of CompoSecure. “As the financial landscape evolves, non-custodial neobanking is set to redefine global commerce. With billions of dollars in stablecoins already transacting across public blockchains, the MetaMask card represents the missing link that turns crypto from an investment into a true, everyday currency like cash, anywhere, anytime.”

The MetaMask Metal Payment Card is scheduled to launch globally in the second quarter of 2025. For more information or to join the waitlist, please visit the MetaMask Portfolio .

About CompoSecure
Founded in 2000, CompoSecure (Nasdaq: CMPO) is a technology partner to market leaders, fintechs and consumers enabling trust for millions of people around the globe. The company combines elegance, simplicity and security to deliver exceptional experiences and peace of mind in the physical and digital world. CompoSecure’s innovative payment card technology and metal cards with Arculus security and authentication capabilities deliver unique, premium branded experiences, enable people to access and use their financial and digital assets and ensure trust at the point of a transaction. For more information, please visit www.CompoSecure.com and www.GetArculus.com .

About Baanx ($BXX)
Baanx is a leading crypto payments and B2B2C digital asset services provider whose portfolio includes major crypto card programmes including CL Card and 1inch Card. This full suite of services offers users full control over their assets. Using the CL Card, users are able to securely spend crypto assets globally with over 90 million merchants. By collaborating with those at the forefront of the emerging financial technology industry (such as Ledger, 1inch, and Mastercard) Baanx is able to elevate their customer experience through innovation.

Baanx.com Ltd is one of the first companies to receive approval from the UK Financial Conduct Authority (FCA), operating Fintech payment services which utilise an Electronic Money Institution (EMI) license UK & EU/EEA and a Credit Broking License (UK). Join us in shaping the future of Trustless Banking as a Service (BaaS). https://baanx.com/

About Consensys
Consensys is the leading blockchain and web3 software company. Since 2014, Consensys has been at the forefront of innovation, pioneering technological developments within the web3 ecosystem. Through our product suite, including the MetaMask platform , Infura , Linea , Diligence , and Phosphor , we have become the trusted collaborator for users, creators, and developers on their path to build and belong in the world they want to see. Whether building a dapp, an NFT collection, a portfolio, or a better future, the instinct to build is universal. Consensys inspires and champions the builder instinct in everyone by making web3 universally easy to use and develop on. To explore our products and solutions, visit https://consensys.io/ .

For CompoSecure: Anthony Piniella
Head of Communications
(917) 208-7724
apiniella@composecure.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/30b168b4-ea3b-4418-ad16-5b3077d4c1f7

SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI ^® , today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation at Digestive Disease Week ^® (DDW) 2025, taking place May 3–6, 2025, in San Diego, CA.

The analysis leverages real-world data from over 100 million U.S. patients and highlights differences in TD incidence rates and timing based on metoclopramide dosing patterns.

“This research builds on our ongoing commitment to understanding metoclopramide’s long-term safety profile,” said Matt D’Onofrio, CEO of Evoke Pharma. “As the only FDA-approved treatment for diabetic gastroparesis, it’s critical that we continue evaluating both efficacy and safety, particularly around concerns like tardive dyskinesia. This real-world data helps clarify risk profiles and supports more informed prescribing decisions for physicians interested in Gimoti. We’re excited to share these findings with the DDW community.”

Details of the poster presentation are as follows:

Abstract Title: Comparison of the Incidence of Tardive Dyskinesia in Patients Receiving Continuous vs Intermittent Oral Metoclopramide

Presenter & Lead Author: Pierantonio Russo, MD, EVERSANA Life Sciences

Presentation Session: Gastroparesis and Small Intestinal Dysmotility

Date & Time: Monday, May 5, 2025, from 12:30 – 1:30 p.m. PT

The abstract will be available via the DDW ePosters site and accessible to attendees through the DDW meeting planner and mobile app after 12:01 a.m. PT on Sunday, May 4, 2025.

Visit Evoke Pharma at DDW 2025:
To learn more about GIMOTI and our latest research, visit Evoke Pharma at booth #917 during DDW.

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.

Visit www.EvokePharma.com for more information.

Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter

About Digestive Disease Week ^® (DDW)

Digestive Disease Week ^® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases nearly 6,000 abstracts and 1,000 invited talks on the latest advances in GI research, medicine, and technology. More information can be found at www.ddw.org .

About Gimoti ^® (metoclopramide) nasal spray

GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information

WARNING: TARDIVE DYSKINESIA

• Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.
• Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.
• Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use .
  

GIMOTI is not recommended for use in:

• Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates .
• Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.

GIMOTI is contraindicated:

• In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.
• When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage mechanical obstruction, or perforation).
• In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.
• In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.
• In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm.
  

Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue. These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Safe Harbor Statement

Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should, ”expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoke’s or EVERSANA’s marketing efforts; Evoke’s commercialization plans, the potential market opportunity for GIMOTI, Evoke’s partnership with ASPN Pharmacies, growth in prescriptions, patients taking GIMOTI and the conversion of prescriptions to fills, and Evoke’s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoke’s and EVERSANA’s ability to successfully drive market demand for GIMOTI; Evoke’s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor & Media Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
dboateng@dkbpartners.net